Sotagliflozin in Patients with Diabetes and Recent Wors

New England Journal of Medicine
384, 117-128
DOI: 10.1056/nejmoa2030183

Citation Report

#	Article	IF	Citations
1	Design of a prospective patientâ€level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European Journal of Heart Failure, 2020, 22, 2393-2398.	7.1	19
2	Heart failure in the last year: progress and perspective. ESC Heart Failure, 2020, 7, 3505-3530.	3.1	52
3	Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOISTâ€WHF in perspective. ESC Heart Failure, 2020, 7, 3261-3267.	3.1	16
4	Discovery and care innovation amidst a pandemic. European Journal of Heart Failure, 2020, 22, 2202-2204.	7.1	0
5	Solute excretion, metabolism, and cardioâ€renoprotection via two distinct mechanisms revolutionize clinical outcomes. Acta Physiologica, 2021, 232, e13589.	3.8	1
6	Sotagliflozin reduces adverse cardiovascular events. Nature Reviews Cardiology, 2021, 18, 74-74.	13.7	0
7	<scp>SOLOISTâ€WHF</scp> and updated metaâ€analysis: sodiumâ€“glucose coâ€transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. European Journal of Heart Failure, 2021, 23, 27-30.	7.1	14
8	Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVIDâ€19: Design and rationale for the DAREâ€19 study. Diabetes, Obesity and Metabolism, 2021, 23, 886-896.	4.4	40
9	Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom. International Journal of Heart Failure, 2021, 3, 205.	2.7	4
10	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. European Heart Journal, 2021, 42, 657-670.	2.2	25
11	Sodiumâ€“glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 17.	6.8	27
12	Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction â€“ aÂpractical approach. Postepy W Kardiologii Interwencyjnej, 2021, 17, 135-140.	0.2	1
13	Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 351-359.	3.6	13
14	Effect of sodiumâ€“glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovascular Diabetology, 2021, 20, 25.	6.8	27
15	Do we need a definition of acute heart failure with preserved ejection fraction?. Annals of Medicine, 2021, 53, 1473-1478.	3.8	0
16	Conference highlights: The 81st Annual (Virtual) conference of the American diabetes association: June 25â€“29, 2021. Journal of Diabetes and Endocrine Practice, 2021, 4, 143.	0.3	0
17	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. European Heart Journal, 2021, 42, 4887-4890.	2.2	11
18	Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. International Journal of Molecular Sciences, 2021, 22, 660.	4.1	15

#	Article	IF	Citations
19	Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. European Heart Journal, 2022, 43, 2968-2970.	2.2	6
20	Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110421.	3.2	12
21	Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110449.	3.2	0
22	Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2021, 172, 108648.	2.8	1
23	Acute heart failure treatment: a light at the end of the tunnel?. European Journal of Heart Failure, 2021, 23, 698-702.	7.1	5
24	New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H838-H853.	3.2	18
25	Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure. Russian Journal of Cardiology, 2021, 26, 4235.	1.4	1
26	Sodiumâ€“glucose coâ€transporter 2 inhibitorsâ€”the first successful treatment for heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2021, 23, 1256-1259.	7.1	2
27	SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Failure Reviews, 2022, 27, 951-960.	3.9	16
28	Heart failure or heart success?. Cardiovascular Research, 2021, 117, e29-e34.	3.8	4
30	Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020. Endocrinology and Metabolism, 2021, 36, 41-50.	3.0	4
31	SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Failure Reviews, 2022, 27, 961-980.	3.9	18
32	Diabetes Management in Patients with Heart Failure. Diabetes and Metabolism Journal, 2021, 45, 158-172.	4.7	9
33	Novel Trial Design: CHIEF-HF. Circulation: Heart Failure, 2021, 14, e007767.	3.9	23
34	Sodiumâ€“glucose coâ€transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial. European Journal of Heart Failure, 2021, 23, 826-834.	7.1	60
35	Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	0
36	Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. Current Opinion in Nephrology and Hypertension, 2021, 30, 361-368.	2.0	3
37	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovascular Diabetology, 2021, 20, 75.	6.8	9

#	Article	IF	Citations
38	Use of <scp>sodiumâ€“glucose</scp> coâ€transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2021, 23, 1012-1022.	7.1	33
39	Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2021, 12, 664502.	3.5	2
40	eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined. Kidney360, 2021, 2, 1042-1047.	2.1	40
41	Association of sodiumâ€glucose cotransporterâ€2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the <scp>CVDâ€REAL</scp> 2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1431-1435.	4.4	12
42	Prevention of heart failure events with sodiumâ€“glucose coâ€transporter 2 inhibitors across a spectrum of cardioâ€renalâ€metabolic risk. European Journal of Heart Failure, 2021, 23, 1002-1008.	7.1	25
43	SGLT-2 Inhibitors in HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1393-1396.	2.8	4
44	Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. Diabetes and Metabolism Journal, 2021, 45, 146-157.	4.7	56
45	SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 2210-2219.	3.1	26
46	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	2.7	30
47	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. European Heart Journal, 2021, 42, 1458-1459.	2.2	4
48	Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. Diabetes Care, 2021, 44, 1236-1241.	8.6	37
49	Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. American Heart Journal, 2021, 233, 86-91.	2.7	38
50	Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	14
51	Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart, 2021, 8, e001585.	2.3	30
52	Medical Therapy of Heart Failure with Reduced Ejection Fractionâ€”A Call for Comparative Research. Journal of Clinical Medicine, 2021, 10, 1803.	2.4	1
53	Cardiovascular Outcomes with Sotagliflozin. New England Journal of Medicine, 2021, 384, 1470-1473.	27.0	2
54	Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. US Cardiology Review, 0, 15, .	0.5	12
55	Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy, 2021, 41, 526-536.	2.6	5

#	Article	IF	Citations
56	A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 632-643.	1.7	31
57	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 531-546.	1.7	170
58	Do SGLT â€2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?. Journal of Diabetes, 2021, 13, 596-600.	1.8	5
59	Clinical Adverse Events Associated with Sodiumâ€“Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2133-2145.	3.6	35
60	Cardiorenal Protection in Diabetic Kidney Disease. Endocrinology and Metabolism, 2021, 36, 256-269.	3.0	10
61	Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. Cardiovascular Diabetology, 2021, 20, 78.	6.8	11
62	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. New England Journal of Medicine, 2021, 384, 1248-1260.	27.0	60
63	Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials. Advances in Therapy, 2021, 38, 2170-2200.	2.9	4
64	Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes?. Circulation, 2021, 144, 4-6.	1.6	24
65	From glucose lowering agents to disease/diabetes modifying drugs: a â€œSIMPLEâ€•approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 92.	6.8	28
66	Sodiumâ€“glucose coâ€transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness. European Journal of Heart Failure, 2021, 23, 1023-1025.	7.1	1
67	Effects of sodiumâ€glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a metaâ€analysis of randomized controlled trials. Cardiovascular Diabetology, 2021, 20, 83.	6.8	20
68	Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e74-e76.	3.0	8
69	Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. Expert Opinion on Drug Safety, 2021, 20, 1-14.	2.4	6
70	Sodiumâ€“glucose coâ€transporter 2 inhibitors: strength of evidence for a cardioâ€renalâ€metabolic therapy. European Journal of Heart Failure, 2021, 23, 1009-1011.	7.1	0
71	SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. Current Cardiology Reports, 2021, 23, 59.	2.9	7
72	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2021, 23, 872-881.	7.1	160
73	Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. Future Cardiology, 2021, 17, 459-473.	1.2	4

#	Article	IF	Citations
74	Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. Circulation Research, 2021, 128, 1468-1486.	4.5	63
75	The effect of sodiumâ€glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studies. Diabetic Medicine, 2021, 38, e14600.	2.3	3
76	Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives. Russian Journal of Cardiology, 2021, 26, 4436.	1.4	3
77	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 539-546.	3.0	22
78	Letter to the Editor regarding the article â€œSGLT2 inhibitors and cardiovascular and renal outcomes: a metaâ€‘analysis and trial sequential analysisâ€. Heart Failure Reviews, 2021, , 1.	3.9	0
79	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart, 2022, 108, 16-21.	2.9	7
80	Vulnerable Phase of Acute Heart Failure and its Association with Hospital Readmissions Reduction Program. Current Problems in Cardiology, 2022, 47, 100904.	2.4	7
81	SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Scientific Reports, 2021, 11, 10293.	3.3	37
82	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. Diabetes Research and Clinical Practice, 2021, 175, 108796.	2.8	11
83	Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial. Diabetes Therapy, 2021, 12, 2101-2113.	2.5	6
84	Rapid evidenceâ€based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 882-894.	7.1	88
85	Timely and individualized heart failure management: need for implementation into the new guidelines. Clinical Research in Cardiology, 2021, 110, 1150-1158.	3.3	18
86	Recent advances in new-onset diabetes mellitus after kidney transplantation. World Journal of Diabetes, 2021, 12, 541-555.	3.5	4
87	SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF. European Journal of Internal Medicine, 2021, 87, 102-103.	2.2	0
88	Mechanisms and Models in Heart Failure. Circulation Research, 2021, 128, 1435-1450.	4.5	24
89	Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction. CJC Open, 2021, 3, 646-657.	1.5	2
90	Design and rationale of the EMPAâ€VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. ESC Heart Failure, 2021, 8, 2580-2590.	3.1	18
91	Diabetes-Related Factors and the EffectsÂof Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. Journal of the American College of Cardiology, 2021, 77, 2366-2377.	2.8	13

#	Article	IF	Citations
92	Epicardial adipose tissue in obesity-related cardiac dysfunction. Heart, 2022, 108, 339-344.	2.9	22
93	Does Combination Therapy With SGLT2 Inhibitors and Reninâ€“Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?. Frontiers in Cardiovascular Medicine, 2021, 8, 679124.	2.4	5
94	Fluid volume regulation in patients with heart failure. Lancet Diabetes and Endocrinology,the, 2021, 9, 256-257.	11.4	2
95	SGLT2 inhibitors in cardiovascular medicine. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e67-e68.	3.0	20
96	Worsening HeartÂFailure Episodes Outside a Hospital Setting in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2021, 9, 374-382.	4.1	23
97	SGLT2 inhibitors: Do we need other evidences?. European Journal of Internal Medicine, 2021, 87, 18-19.	2.2	0
98	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. International Journal of Molecular Sciences, 2021, 22, 5863.	4.1	48
100	Eligibility of outpatients with chronic heart failure for sodiumâ€“glucose coâ€transporterâ€2 inhibitors. ESC Heart Failure, 2021, 8, 2951-2958.	3.1	8
101	From Systemic Inflammation to Myocardial Fibrosis. Circulation Research, 2021, 128, 1451-1467.	4.5	132
102	Investigating the effect of an education program on diabetes and lipid lowering medication usage following coronary artery bypass graft surgery. Internal Medicine Journal, 2021, , .	0.8	6
103	Use of loop diuretics in chronic heart failure: do we adhere to the <scp>Hippocratian</scp> principle â€˜do no harmâ€™?. European Journal of Heart Failure, 2021, 23, 1068-1075.	7.1	4
104	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545.	0.5	47
105	Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem. Metabolism Open, 2021, 10, 100089.	2.9	6
106	Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis. European Journal of Endocrinology, 2021, 184, 783-790.	3.7	3
107	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 2021, 23, 1217-1225.	7.1	195
109	Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials. Cardiovascular Diagnosis and Therapy, 2021, 11, 699-706.	1.7	4
110	Sodiumâ€“glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. CKJ: Clinical Kidney Journal, 2021, 14, 2463-2471.	2.9	12
111	Sodium-glucose cotransporter 2Âinhibitors: aÂpractical guide for the Dutch cardiologist based on real-world experience. Netherlands Heart Journal, 2021, 29, 490-499.	0.8	3

#	Article	IF	Citations
112	SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials. Kidney Medicine, 2021, 3, 732-744.e1.	2.0	10
113	Sodiumâ€“glucose cotransporter 2 inhibitorâ€induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 2631-2636.	3.1	6
116	Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial. Cardiovascular Diabetology, 2021, 20, 105.	6.8	22
117	Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF. Cardiovascular Drugs and Therapy, 2021, 35, 1077-1078.	2.6	3
118	Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opinion on Pharmacotherapy, 2021, 22, 1847-1855.	1.8	18
119	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs, 2021, 81, 1243-1255.	10.9	2
121	The effects of antidiabetic agents on heart failure. Netherlands Heart Journal, 2022, 30, 65-75.	0.8	2
122	Recent advances in pharmacological treatment of heart failure. European Journal of Clinical Investigation, 2021, 51, e13624.	3.4	19
124	Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials. Diabetology International, 2022, 13, 325-329.	1.4	2
125	Decoding empagliflozinâ€™s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. Scientific Reports, 2021, 11, 12025.	3.3	23
126	Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 2022, 108, 312-320.	2.9	2
127	Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance. Annales De Cardiologie Et D'Angeiologie, 2022, 71, 41-52.	0.6	8
128	Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention. Current Atherosclerosis Reports, 2021, 23, 50.	4.8	7
129	HeartÂFailure and Chronic Kidney Disease Patients. Journal of the American College of Cardiology, 2021, 78, 344-347.	2.8	4
130	Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares. Russian Journal of Cardiology, 2021, 26, 4534.	1.4	1
131	Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. Drug Design, Development and Therapy, 2021, Volume 15, 3057-3069.	4.3	11
132	Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 691907.	2.4	26
133	Cardio-renal benefits of sodiumâ€“glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 311-321.	3.0	25

#	Article	IF	Citations
134	Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. American Journal of Cardiovascular Drugs, 2021, , 1.	2.2	7
136	Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease. Pharmaceuticals, 2021, 14, 751.	3.8	13
137	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. European Journal of Heart Failure, 2021, 23, 1250-1255.	7.1	17
138	Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches. Rational Pharmacotherapy in Cardiology, 2021, 17, 476-483.	0.8	0
139	Role of Guideline Directed Medical Therapy Doses and Optimization in Patients Hospitalized With Decompensated Systolic Heart Failure. American Journal of Cardiology, 2021, 151, 64-69.	1.6	8
141	Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?. Drugs, 2021, 81, 1365-1371.	10.9	19
142	Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failureâ€”Optimizing Therapy With the Need for Speed. JAMA Cardiology, 2021, 6, 743.	6.1	125
143	Sodiumâ€“glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure. Journal of Cardiovascular Pharmacology, 2021, 78, 501-514.	1.9	9
144	Cardiac, renal, and metabolic effects of sodiumâ€“glucose coâ€transporter 2 inhibitors: a position paper from the European Society of Cardiology adâ€hoc task force on sodiumâ€“glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275.	7.1	36
145	Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. Medicine (United) Tj ETQq1 1 0.784314 rgBT /O		
146	Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Research and Care, 2021, 9, e002300.	2.8	12
147	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501.	5.9	49
148	Sodiumâ€glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. ESC Heart Failure, 2021, 8, 4093-4118.	3.1	11
149	Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials. Medicine (United States), 2021, 100, e26561.	1.0	1
150	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet, The, 2021, 398, 262-276.	13.7	222
151	Tandem positive action of SGLT2 inhibitors and ARNI in patients with heart failure. Acta Diabetologica, 2021, 58, 1579-1580.	2.5	5
152	Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial. ESC Heart Failure, 2021, 8, 4346-4352.	3.1	15
153	Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients. Heart Failure Reviews, 2023, 28, 733-744.	3.9	19

#	Article	IF	Citations
154	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovascular Research, 2022, 118, 2231-2252.	3.8	23
155	Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovascular Diabetology, 2021, 20, 169.	6.8	17
156	Introduction to Nephrocardiology. Cardiology Clinics, 2021, 39, 295-306.	2.2	4
157	SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. Cardiovascular Drugs and Therapy, 2022, 36, 1091-1108.	2.6	2
158	Vericiguat for Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2021, 23, 144.	2.9	19
159	Diabetes Mellitus and Heart Failure. Journal of Clinical Medicine, 2021, 10, 3682.	2.4	27
160	Prospective association of serum adipocyte fatty acidâ€binding protein with heart failure hospitalization in diabetes. ESC Heart Failure, 2021, 8, 3964-3974.	3.1	2
161	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace, 2021, 23, 1873-1891.	1.7	10
162	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia, 2021, 40, 975-983.	0.5	6
163	New Antidiabetes Medications and Their Cardiovascular and Renal Benefits. Cardiology Clinics, 2021, 39, 335-351.	2.2	10
164	Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature. Cardiology Research, 2021, 12, 210-218.	1.1	7
165	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	3.9	32
166	Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review. Heart, 2022, 108, 593-605.	2.9	3
167	Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2021, 10, 3540.	2.4	6
168	ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes. European Heart Journal Supplements, 2021, 23, C184-C195.	0.1	5
169	Efficacy and safety of sotagliflozin in patients with type <scp>2</scp> diabetes and severe renal impairment. Diabetes, Obesity and Metabolism, 2021, 23, 2632-2642.	4.4	30
170	Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage. European Heart Journal, 2021, 42, 4961-4963.	2.2	6
171	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294.	1.6	195

#	Article	IF	Citations
172	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 2021, 27, 888-895.	1.7	14
173	New Drugs for Heart Failure: What is the Evidence in Older Patients?. Journal of Cardiac Failure, 2022, 28, 316-329.	1.7	1
174	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 2021, 42, 3727-3738.	2.2	125
175	Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). American Journal of Cardiology, 2021, 158, 59-65.	1.6	1
176	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
177	A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. Drugs, 2021, 81, 1491-1511.	10.9	18
178	SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction â€" A Win against a Formidable Foe. New England Journal of Medicine, 2021, 385, 1522-1524.	27.0	14
179	Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2022, 20, 90-102.	1.0	3
180	Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annual Review of Medicine, 2022, 73, 321-337.	12.2	52
182	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102035.	2.6	9
183	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
184	Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. Circulation Reports, 2021, 3, 440-448.	1.0	18
185	Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. European Journal of Internal Medicine, 2021, 90, 10-15.	2.2	6
186	The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis. Cardiology Research and Practice, 2021, 2021, 1-11.	1.1	22
187	Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines, 2021, 9, 1356.	3.2	45
188	Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes. Journal of Diabetes and Its Complications, 2021, 35, 108057.	2.3	1
189	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. Cardiology, 2021, , .	1.4	2
190	The sodiumâ€"glucose coâ€transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. European Journal of Heart Failure, 2021, 23, 1673-1676.	7.1	8

#	Article	IF	Citations
191	Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy. World Journal of Cardiology, 2021, 13, 464-471.	1.5	3
192	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure, 2022, 28, 93-112.	1.7	15
194	A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. American Journal of Medicine, 2021, 134, 1076-1084.	1.5	3
195	Sodiumâ€Glucose Coâ€Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e022222.	3.7	38
196	Sotagliflozin for patients with type <scp>2</scp> diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 106-114.	4.4	19
197	Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload. Frontiers in Physiology, 2021, 12, 738594.	2.8	11
198	Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population. Drugs - Real World Outcomes, 2022, 9, 53-62.	1.6	5
199	The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors. Journal of Diabetes and Its Complications, 2021, 35, 108052.	2.3	7
200	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. Journal of Cardiac Failure, 2021, 27, 1027-1030.	1.7	0
201	Heart failure with preserved ejection fraction: a stepchild no more!. European Heart Journal, 2021, 42, 3900-3901.	2.2	13
202	Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy. Journal of Clinical Medicine, 2021, 10, 4409.	2.4	5
203	Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?. Journal of Clinical Medicine, 2021, 10, 4325.	2.4	3
204	Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. Annual Review of Pharmacology and Toxicology, 2022, 62, 109-120.	9.4	6
205	Analysis of robustness of the landmark Cardiovascular outcome trials of antidiabetic drugs â€“ A systematic review. Current Diabetes Reviews, 2021, 17, .	1.3	0
206	2021 Consensus Pathway of the TaiwanÂSociety of Cardiology on NovelÂTherapyÂfor Type 2 Diabetes. JACC Asia, 2021, 1, 129-146.	1.5	1
207	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2021, 27, 1404-1444.	1.7	60
208	Effects of SGLT2 Inhibitors beyond Glycemic Controlâ€”Focus on Myocardial SGLT1. International Journal of Molecular Sciences, 2021, 22, 9852.	4.1	9
209	Heart failure with mid-range or mildly reduced ejection fraction. Nature Reviews Cardiology, 2022, 19, 100-116.	13.7	156

#	Article	IF	Citations
210	Sodiumâ€Glucose Cotransporter 2 Inhibitors, Allâ€Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Metaâ€Analysis and Metaâ€Regression. Journal of the American Heart Association, 2021, 10, e019918.	3.7	8
212	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circulation Journal, 2021, 85, 2252-2291.	1.6	80
213	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. International Journal of Cardiology, 2021, 338, 248-257.	1.7	1
214	Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review. Journal of Clinical Medicine, 2021, 10, 4497.	2.4	10
215	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2021, 174, 1528-1541.	3.9	52
216	Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?. Cardiovascular Drugs and Therapy, 2023, 37, 315-321.	2.6	3
217	The effect of sodium-glucose link transporter 2 inhibitors on heart failure end points in people with type 2 diabetes mellitus: a systematic review and meta-analysis. British Journal of Diabetes, 0, , .	0.2	1
218	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clinical Research in Cardiology, 2022, 111, 428-439.	3.3	22
219	The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia, 2021, 64, 2676-2686.	6.3	44
220	SGLT2 Inhibitors and Their Mode of Action in Heart Failureâ€”Has the Mystery Been Unravelled?. Current Heart Failure Reports, 2021, 18, 315-328.	3.3	43
221	Congestion in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 575-586.	2.1	13
222	Improving Quality of Life in Heart Failure. Current Cardiology Reports, 2021, 23, 159.	2.9	22
223	Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases. Medicine (United States), 2021, 100, e27362.	1.0	7
224	Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?. European Journal of Pharmacology, 2021, 908, 174378.	3.5	3
225	Les nouvelles thÃ©rapeutiques du diabÃ¨te. La Presse MÃ©dicale Formation, 2021, 2, 574-574.	0.1	0
226	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630.	3.2	3
227	Efficacy of Sodium-Glucose Cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: An updated meta-analysis. Annals of Medicine and Surgery, 2021, 70, 102796.	1.1	1
228	Disease-modifier Drugs in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 561-573.	2.1	2

#	Article	IF	Citations
229	Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102282.	3.6	1
230	A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure. Cardiology Research, 2021, 12, 60-66.	1.1	17
231	Cardioprotection with Yet Another SGLT2 Inhibitor â€" An Embarrassment of Riches. New England Journal of Medicine, 2021, 384, 179-181.	27.0	4
232	Heart failure drug treatment: the fantastic four. European Heart Journal, 2021, 42, 681-683.	2.2	131
233	Sodiumâ€"glucose Cotransporter 2 Inhibitorsâ€™ Rise to the Backbone of Heart Failure Management: A Clinical Review. Heart International, 2021, 15, 42.	1.4	0
234	Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention. Current Atherosclerosis Reports, 2021, 23, 4.	4.8	5
235	Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment. Korean Circulation Journal, 2021, 51, 399.	1.9	9
236	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and metaâ€analysis. ESC Heart Failure, 2020, 7, 3298-3309.	3.1	76
237	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	2.2	71
238	SGLT2 inhibitors: the statins of the 21st century. European Heart Journal, 2022, 43, 1029-1030.	2.2	45
239	Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism: Clinical and Experimental, 2022, 126, 154918.	3.4	42
240	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. European Cardiology Review, 2021, 16, e40.	2.2	9
241	Intersection Between Diabetes and Heart Failure: Is SGLT2i the â€œOne Stone for Two Birdsâ€•Approach?. Current Cardiology Reports, 2021, 23, 171.	2.9	2
242	The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. Cells, 2021, 10, 2699.	4.1	7
243	Effects of an outpatient intervention comprising nurseâ€led nonâ€invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (<scp>AMULET</scp> study): a randomised controlled trial. European Journal of Heart Failure, 2022, 24, 565-577.	7.1	23
244	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPAâ€REG OUTCOME trial. ESC Heart Failure, 2021, 8, 4517-4527.	3.1	46
245	Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 200.	6.8	10
246	Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 383-390.	4.0	9

#	Article	IF	Citations
247	Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Failure Reviews, 2023, 28, 709-721.	3.9	14
248	Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 664533.	3.5	6
249	Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Diseaseâ€"From Bench to Bedside. Frontiers in Physiology, 2021, 12, 755060.	2.8	13
250	Benefits and harms of sodiumâ€glucose coâ€transporterâ€2 inhibitors (SGLT2â€) and reninâ€"angiotensinâ€"aldosterone system inhibitors (RAASâ€) versus SGLT2â€s alone in patients with type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Endocrinology, Diabetes and Metabolism, 2022, 5, e00303.	2.4	12
251	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 78, 1525-1537.	2.8	25
252	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013650.	2.8	28
253	Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 778284.	2.4	2
254	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine, 2021, 41, 101163.	7.1	33
255	Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783.	4.1	32
256	SelecciÃ³n de lo mejor del aÃ±o 2018 en riesgo vascular y rehabilitaciÃ³n cardiaca. REC: CardioClinics, 2019, 54, 44-50.	0.1	0
257	Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction. American Journal of Cardiology, 2021, , .	1.6	0
258	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960.	30.7	299
260	Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes. Journal of the American Heart Association, 2021, 10, e022667.	3.7	6
261	The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?. Expert Opinion on Pharmacotherapy, 2021, , 1-10.	1.8	1
262	Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. Heart Failure Reviews, 2023, 28, 683-695.	3.9	3
263	New evidence from the scientific sessions 2020 of the American Heart Association. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e1-e1.	3.0	0
264	Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2022, 29, e227-e229.	1.8	18
265	â€˜Time is prognosisâ€™ in heart failure: timeâ€toâ€treatment initiation as a modifiable risk factor. ESC Heart Failure, 2021, 8, 4444-4453.	3.1	37

#	Article	IF	Citations
266	Cardiovascular benefits beyond urinary glucose excretion: <scp>A hypothesis generated from two metaâ€analyses</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 550-554.	4.4	3
267	EMPEROR-Preserved: A promise fulfilled. Cell Metabolism, 2021, 33, 2099-2103.	16.2	8
268	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy, 2022, 36, 561-567.	2.6	16
269	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology, 2021, 20, 218.	6.8	38
270	The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge. Postgraduate Medicine, 2022, 134, 11-13.	2.0	2
271	Effectiveness and safety of empagliflozin in routine care patients: Results from the <scp>EMPagliflozin compaRative effectIveness</scp> and <scp>SafEty</scp> (<scp>EMPRISE</scp>) study. Diabetes, Obesity and Metabolism, 2022, 24, 442-454.	4.4	29
272	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors forÂHeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2021, 78, 2004-2012.	2.8	48
273	HeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2021, 78, 2013-2016.	2.8	1
274	SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation. Cleveland Clinic Journal of Medicine, 2021, 88, 601-606.	1.3	2
275	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2021, 12, 752370.	2.8	12
276	The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure. Cureus, 2021, 13, e19379.	0.5	1
277	Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction-A Specific HFpEF Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 720690.	2.4	3
278	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230.	4.4	17
279	The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. Journal of Personalized Medicine, 2021, 11, 1249.	2.5	7
280	Crosstalk between Sodiumâ€“Glucose Cotransporter Inhibitors and Sodiumâ€“Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases. International Journal of Molecular Sciences, 2021, 22, 12677.	4.1	6
281	Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. Journal of the American Geriatrics Society, 2022, 70, 862-871.	2.6	10
282	The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2021, 7, e18.	3.0	22
283	Relationship of Nonalcoholic Fatty Liver Disease and HeartÂFailure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 918-932.	4.1	41

#	Article	IF	Citations
284	Neuroprotective Effect of SGLT2 Inhibitors. Molecules, 2021, 26, 7213.	3.8	79
285	SGLT-2 inhibitors as cardio-renal protective agents. Metabolism: Clinical and Experimental, 2022, 127, 154937.	3.4	20
286	Sodiumâ€“Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials. American Journal of Therapeutics, 2022, 29, e199-e204.	0.9	6
287	Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease. Kidney Research and Clinical Practice, 2021, 40, 555-565.	2.2	8
288	Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice. Russian Journal of Cardiology, 2021, 26, 4699.	1.4	1
289	A Natural Language Processingâ€“Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. JAMA Network Open, 2021, 4, e2135152.	5.9	21
290	The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors. Expert Opinion on Pharmacotherapy, 2022, 23, 321-325.	1.8	7
291	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 554-563.	1.7	4
292	Cardiovascular benefit of SGLT2 inhibitors. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 142-155.	6.1	6
293	Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clinical Drug Investigation, 2022, 42, 1-16.	2.2	4
294	Navigating between Scylla and Charybdis: challenges and strategies for implementing guidelineâ€directed medical therapy in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 1999-2007.	7.1	22
295	Efficacy of Dapagliflozin in Black Versus White Patients With HeartÂFailure and Reduced Ejection Fraction. JACC: Heart Failure, 2022, 10, 52-64.	4.1	10
296	Glucagon-like peptide-1 receptor agonists and sodiumâ^'glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. European Journal of Internal Medicine, 2022, 96, 26-33.	2.2	7
298	Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	1.9	1
299	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. Heart Failure Reviews, 2023, 28, 667-681.	3.9	14
300	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. American Journal of Cardiology, 2021, 161, 118-120.	1.6	2
301	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials. Frontiers in Endocrinology, 2021, 12, 743807.	3.5	7
302	Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. European Journal of Clinical Pharmacology, 2021, , 1.	1.9	0

#	Article	IF	Citations
303	Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes. European Endocrinology, 2021, 17, 92.	1.5	1
304	Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease. JAMA Network Open, 2022, 5, e2142078.	5.9	31
305	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. European Heart Journal, 2022, 43, 367-376.	2.2	13
306	Mitochondrial dysfunction and mitochondrial therapies in heart failure. Pharmacological Research, 2022, 175, 106038.	7.1	35
307	Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: Mechanism progresses and challenges. Pharmacological Research, 2022, 176, 106049.	7.1	7
308	Glycaemic Control in Diabetes. Handbook of Experimental Pharmacology, 2021, , 47-71.	1.8	1
309	Diuretics and Clinical Management of Congestion in Heart Failure: A Review. , 2021, 1, 55-62.		1
310	Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fractionâ€"A Specific HFpEF Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 720690.	2.4	25
311	Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		2
312	Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart, 2022, 108, 1342-1350.	2.9	81
313	Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure. International Journal of Heart Failure, 2022, 4, 75.	2.7	10
314	Comparative effectiveness of cardiovascular, renal and safety outcomes of secondâ€line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network metaâ€analysis of randomised controlled trials. Diabetic Medicine, 2022, 39, e14780.	2.3	13
315	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 557-567.	3.0	20
316	Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 787810.	2.4	6
317	SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis, 2022, 11, 1.	3.5	25
318	SelecciÃ³n de lo mejor del aÃ±o 2021 en insuficiencia cardiaca. REC: CardioClinics, 2022, 57, S71-S77.	0.1	0
319	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. Diabetes Therapy, 2022, 13, 241-250.	2.5	11
320	Sodiumâ€"glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	7.1	67

#	Article	IF	Citations
321	Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip. Cureus, 2022, 14, e21768.	0.5	1
322	Ejection fraction in heart failure: just become Emperor's new clothes?. European Journal of Heart Failure, 2022, 24, 351-352.	7.1	3
323	The role of SGLT2 inhibitors in heart failure. , 0, 1, 2.		0
324	Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes. Heart Failure Reviews, 2022, , 1.	3.9	4
325	The year in cardiovascular medicine 2021: diabetes and metabolic disorders. European Heart Journal, 2022, 43, 263-270.	2.2	7
326	SGLT2 Inhibitors and Their Antiarrhythmic Properties. International Journal of Molecular Sciences, 2022, 23, 1678.	4.1	24
327	Robustness of outcomes in trials evaluating sodiumâ€“glucose coâ€transporter 2 inhibitors for heart failure. ESC Heart Failure, 2022, , .	3.1	4
328	Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis. PLoS ONE, 2022, 17, e0261986.	2.5	15
329	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, CIR0000000000001040.	1.6	193
330	Response to the Letter on â€œThe Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitusâ€• Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	0
331	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 1066-1076.	7.1	28
332	SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice. International Journal of Cardiology, 2022, 351, 66-70.	1.7	9
333	Letter to the Editor Regarding â€œThe Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitusâ€• Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	0
334	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
335	Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Current Diabetes Reports, 2022, 22, 39-52.	4.2	55
336	Sodiumâ€glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a metaâ€analysis. ESC Heart Failure, 2022, 9, 942-946.	3.1	23
337	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
338	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Journal of the American College of Cardiology, 2022, 79, 432-444.	2.8	21

#	Article	IF	Citations
339	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs, 2022, 82, 375-405.	10.9	7
340	Outcome trial data on sodium glucose cotransporter-2 inhibitors: Putting clinical benefits and risks in perspective. International Journal of Cardiology, 2022, 349, 96-98.	1.7	1
341	Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept. Clinical Drug Investigation, 2022, 42, 113-125.	2.2	2
342	New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure. Advances in Medical Sciences, 2022, 67, 95-102.	2.1	3
343	Sacubitril/valsartan, sodiumâ€glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 425-438.	2.5	5
344	Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. Heart Failure Reviews, 2022, , .	3.9	0
345	Early in-hospital initiation and optimization of comprehensive disease-modifying pharmacotherapy in patients with heart failure with reduced ejection fraction: a time for the paradigm shift. Expert Review of Cardiovascular Therapy, 2022, , 1-4.	1.5	3
346	Four-Drug Therapy For Heart Failure with Reduced LV Ejection Fraction - Here and Now. Journal of Cardiac Failure, 2022, , .	1.7	0
347	SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction. Drugs and Aging, 2022, 39, 185-190.	2.7	4
348	A promise unfulfilled: the use of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction. European Journal of Heart Failure, 2022, 24, 548-550.	7.1	1
349	Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nature Reviews Nephrology, 2022, 18, 294-306.	9.6	64
350	Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care, 2022, 45, 965-974.	8.6	13
351	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovascular Diabetology, 2022, 21, 20.	6.8	36
352	Nueva guÃa de insuficiencia cardiaca de la HFA-ESC 2021. Un enfoque prÃ¡ctico e integral. Revista Espanola De Cardiologia, 2022, , .	1.2	1
353	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, 43, 416-424.	2.2	144
354	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2022. Diabetes Care, 2022, 45, S144-S174.	8.6	282
355	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Korean Circulation Journal, 2022, 52, 173.	1.9	9
356	Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities. Handbook of Experimental Pharmacology, 2022, , 269-307.	1.8	4

#	Article	IF	Citations
357	New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?. Journal of Cardiology, 2023, 81, 26-32.	1.9	3
358	Genetic variation in sodium glucose coâ€transporter 1 and cardiac structure and function at middle age. ESC Heart Failure, 2022, 9, 1496-1501.	3.1	1
359	Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. Endocrinology and Metabolism, 2022, 37, 26-37.	3.0	20
360	Growing role of SGLT2i in heart failure: evidence from clinical trials. Expert Review of Clinical Pharmacology, 2022, 15, 147-159.	3.1	8
361	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Frontiers in Pharmacology, 2022, 13, 800490.	3.5	21
362	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes, 2022, 16, 223-244.	1.8	15
363	Diabetes mellitus and heart failure: an update on pathophysiology and therapy. Minerva Cardiology and Angiology, 2022, , .	0.7	5
364	The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine, 2022, 28, 809-813.	30.7	107
365	Review of non-insulin antidiabetic pharmacotherapy in patients with heart failure diabetes mellitus in the Czech Republic in 2018. Cor Et Vasa, 2022, 64, 20-24.	0.1	1
366	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). Cardiovascular Diabetology, 2022, 21, 34.	6.8	10
367	Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence. Current Cardiology Reports, 2022, 24, 567-576.	2.9	2
368	Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Minerva Cardiology and Angiology, 2023, 71, .	0.7	6
369	Development and Current Role of SGLT Inhibition in Cardiorenal Metabolic Syndrome. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, 593-604.	1.9	1
370	Response of Growth Hormones and Cortisol to One Session of Moderate-Intensity Endurance Exercise in Patients with Type 2 Diabetes: A Quasi-experimental Study. Medical Journal of the Islamic Republic of Iran, 0, , .	0.9	0
371	Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 2336.	4.1	4
372	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574.	30.7	341
373	An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences, 2022, 23, 3651.	4.1	67
374	New 2021 ESC/HFA heart failure guidelines. A practical comprehensive approach. Revista Espanola De Cardiologia (English Ed), 2022, 75, 548-548.	0.6	3

#	Article	IF	Citations
375	SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failureâ€"A Concise Review. Journal of Clinical Medicine, 2022, 11, 1470.	2.4	16
376	Preventing allâ€cause hospitalizations in type 2 diabetes with sodiumâ€glucose cotransporterâ€2 inhibitors and <scp>glucagonâ€like peptide</scp>â€1 receptor agonists: A narrative review and proposed clinical approach. Diabetes, Obesity and Metabolism, 2022, 24, 969-982.	4.4	5
377	Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors. Expert Review of Cardiovascular Therapy, 2022, 20, 223-232.	1.5	4
378	Drugâ€"Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Drug Safety, 2022, 45, 287-295.	3.2	7
379	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712.	1.6	57
380	Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovascular Diabetology, 2022, 21, 47.	6.8	49
381	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077.	1.7	23
382	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197.	4.1	75
383	A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?. Current Cardiology Reports, 2022, , 1.	2.9	2
384	Prevalence and Prognostic Relevance of Isolated Tubular Dysfunction in Patients With Acute Heart Failure. Circulation Journal, 2022, 86, 709-714.	1.6	3
385	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e10.	3.0	0
386	Modern Approaches to Treatment of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus. UkraÃ¯nsÊ¹kij Å¾urnal Medicini BÃ¬ologÃ¬Ã¯ Ta Sportu, 2022, 7, 14-31.	0.2	1
387	Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials. American Journal of Cardiovascular Drugs, 2022, 22, 299-323.	2.2	16
388	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, 2022, 13, 847-872.	2.5	5
389	Intramuscular injection of sotagliflozin promotes neovascularization in diabetic mice through enhancing skeletal muscle cells paracrine function. Acta Pharmacologica Sinica, 2022, 43, 2636-2650.	6.1	5
390	Role of new drug therapies and innovative procedures in older patients with heart failure: from trials to clinical practice. Minerva Medica, 2022, , .	0.9	2
391	Sodiumâ€glucose cotransporterâ€2 inhibitors in heart failure: an updated metaâ€analysis. ESC Heart Failure, 2022, 9, 1942-1953.	3.1	9
392	Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. Journal of Cardiovascular Translational Research, 2022, 15, 944-956.	2.4	21

#	Article	IF	Citations
393	Effects of Dapagliflozin in Asian Patients With HeartÂFailure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	1.5	2
394	Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis. Frontiers in Endocrinology, 2022, 13, 850836.	3.5	5
395	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With HeartÂFailure and Diabetes. JACC: Heart Failure, 2022, 10, 198-210.	4.1	16
396	A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease. American Journal of Cardiovascular Drugs, 2022, 22, 357-361.	2.2	4
397	Heart failure in adults with congenital heart disease. International Journal of Cardiology, 2022, 357, 39-45.	1.7	17
398	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy, 2022, 13, 889-911.	2.5	2
399	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care, 2022, 45, 1007-1012.	8.6	4
400	The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. Journal of Clinical Medicine, 2022, 11, 1904.	2.4	4
401	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 3587.	4.1	48
402	Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. Expert Opinion on Pharmacotherapy, 2022, 23, 673-680.	1.8	3
403	Evaluating the Initiation of Sodium/Glucose Cotransporter 2 Inhibitors within 2 Weeks of an Acute Hospital Admission: A Systematic Review and Meta-Analysis of Nine Clinical Trials. Medical Principles and Practice, 2022, 31, 215-223.	2.4	0
404	Relationship of Dapagliflozin WithÂSerumÂSodium. JACC: Heart Failure, 2022, 10, 306-318.	4.1	10
405	Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure. American Journal of Cardiology, 2022, , .	1.6	0
406	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
407	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 2022, 21, 50.	6.8	8
408	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288.	1.6	65
409	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	2.8	774
410	Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. , 2022, 238, 108185.		16

#	Article	IF	Citations
411	Low glucose metabolizing capacity and not insulin resistance is primary etiology of type 2 Diabetes Mellitus: A hypothesis. Medical Hypotheses, 2022, 162, 110804.	1.5	0
412	Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. Journal of Molecular and Cellular Cardiology, 2022, 167, 17-31.	1.9	52
413	Why do SGLT2 Inhibitors Act as Cardio-renal Protective even in Non-diabetics?. Japanese Journal of Clinical Pharmacology and Therapeutics, 2021, 52, 157-164.	0.1	0
414	Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	4.0	0
415	Medical management of acute heart failure. Faculty Reviews, 2021, 10, 82.	3.9	6
416	Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Advances in Therapy, 2022, 39, 845-861.	2.9	13
417	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1016-1030.	1.7	5
419	Three new categories of hypoglycaemic agents and various cardiovascular diseases: A metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 636-642.	1.5	3
420	A year in heart failure: an update of recent findings. ESC Heart Failure, 2021, 8, 4370-4393.	3.1	28
421	Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey. Frontiers in Cardiovascular Medicine, 2021, 8, 810791.	2.4	12
422	Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression. Current Opinion in Nephrology and Hypertension, 2022, 31, 205-211.	2.0	1
423	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 975-983.	0.2	0
424	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovascular Diabetology, 2021, 20, 236.	6.8	63
425	Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Scoreâ€“matched Population-based Cohort Study. Canadian Journal of Diabetes, 2022, 46, 392-403.e13.	0.8	6
426	Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1349-1354.	1.7	6
428	Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. Journal of Clinical Medicine, 2022, 11, 137.	2.4	15
429	Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. Cardiology Journal, 2021, 28, 962-969.	1.2	1
430	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	2.2	8

#	Article	IF	Citations
431	Diuretics in Treatment of Heart Failure. , 2022, 2, 86-93.		0
432	Essential Therapy for Heart Failure with Preserved Ejection Fraction in 2022. , 2022, 2, 55-63.		0
433	SGLT2 Inhibitors and Sacubitril-Valsartan: How Trial Results will Revolutionize the Treatment of Heart Failure with Mildly Reduced Ejection Fraction. , 2022, 2, 67-71.		0
434	Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210869.	2.5	12
435	Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure. ESC Heart Failure, 2022, , .	3.1	2
436	Sodiumâ€“Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure. Annals of Internal Medicine, 2022, 175, 851-861.	3.9	23
437	Practical outpatient management of worsening chronic heart failure. European Journal of Heart Failure, 2022, 24, 750-761.	7.1	27
438	Development and Validation of a Novel Nomogram to Predict Improved Left Ventricular Ejection Fraction in Patients With Heart Failure After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion. Frontiers in Cardiovascular Medicine, 2022, 9, 864366.	2.4	0
439	GuÃa ESC 2021 sobre el diagnÃ³stico y tratamiento de la insuficiencia cardiaca aguda y crÃ³nica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	1.2	40
440	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Cardiologia Croatica, 2022, 17, 27-43.	0.0	1
441	Cardiovascular and renal outcomes of initial combination therapy with glucoseâ€lowering agents versus a stepwise approach in newly diagnosed or treatmentâ€naÃ¯ve type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1469-1482.	4.4	0
442	Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from <scp>REPORTâ€HF</scp> (International Registry to assess <scp>mEdical</scp> Practice with) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Failure, 2022, . .	7.1	12
443	Global Benefit of SGLT2 Inhibitors in HeartÂFailure With Reduced EjectionÂFraction. JACC Asia, 2022, 2, 154-156.	1.5	0
444	What's all the fuss about a new guideline?. European Journal of Heart Failure, 2022, 24, 743-745.	7.1	0
445	Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis. Diabetes Research and Clinical Practice, 2022, 187, 109871.	2.8	7
446	Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. Journal of Geriatric Cardiology, 2021, 18, 783-795.	0.2	7
447	Kardiologie. , 2022, , 291-388.		0
448	Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2022, 46, 843-854.	4.7	4

#	Article	IF	Citations
449	Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. Cardiac Failure Review, 0, 8, .	3.0	1
450	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. Journal of Molecular Cell Biology, 2022, 14, .	3.3	16
451	Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease. Current Cardiology Reviews, 2022, 18, .	1.5	1
452	FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. Scientific Reports, 2022, 12, 7326.	3.3	8
454	Sodiumâ€Glucose Cotransporterâ€2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. Basic and Clinical Pharmacology and Toxicology, 2022, , .	2.5	1
455	Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Failure Reviews, 2023, 28, 585-596.	3.9	11
456	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of Cardiac Failure, 2022, 28, 1050-1062.	1.7	19
457	Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports, 2022, 7, 1463-1476.	0.8	59
458	Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?. Endocrine Practice, 2022, 28, 795-801.	2.1	5
459	The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. Pharmacological Research, 2022, 180, 106243.	7.1	25
460	Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview. Nefrologia, 2022, 42, 145-162.	0.4	2
461	Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Research and Clinical Practice, 2022, 188, 109927.	2.8	18
462	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovascular Diabetology, 2022, 21, 74.	6.8	82
463	Headâ€toâ€head comparison between recommendations by the <scp>ESC</scp> and <scp>ACC</scp>/<scp>AHA</scp>/<scp>HFSA</scp> heart failure guidelines. European Journal of Heart Failure, 2022, 24, 916-926.	7.1	18
464	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 2058-2068.	2.8	41
465	Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 2022, 253, 86-98.	2.7	48
466	Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?. Journal of Nephrology, 2022, , .	2.0	5
467	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1927-1938.	4.4	10

#	Article	IF	Citations
468	Year in Review 2021: Noteworthy Literature in Cardiothoracic Anesthesia. Seminars in Cardiothoracic and Vascular Anesthesia, 2022, 26, 107-119.	1.0	1
469	Inflammatory Mechanisms of Diabetes and Its Vascular Complications. Biomedicines, 2022, 10, 1168.	3.2	21
470	Shortâ€term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (<scp>DAPAâ€VO₂</scp>): a randomized clinical trial. European Journal of Heart Failure, 2022, 24, 1816-1826.	7.1	22
471	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2022, 15, 2186-2199.	2.9	9
472	Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	5
473	Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	9
474	Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. Open Heart, 2022, 9, e001936.	2.3	12
475	Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacistâ€™s Perspective. Frontiers in Endocrinology, 2022, 13, .	3.5	2
476	Gliflozins in the Management of Cardiovascular Disease. New England Journal of Medicine, 2022, 386, 2024-2034.	27.0	113
477	Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients. Journal of Clinical Medicine, 2022, 11, 2935.	2.4	4
478	Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes?. European Medical Journal (Chelmsford,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 337	3.0	0
479	The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review. Cureus, 2022, , .	0.5	1
480	Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. American Heart Journal, 2022, 251, 127-136.	2.7	5
481	Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease. Diabetes and Metabolism Journal, 2022, 46, 701-712.	4.7	8
482	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690.	8.6	109
483	Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. Journal of Clinical Medicine, 2022, 11, 3192.	2.4	10
484	Promise of sodiumâ€“glucose coâ€transporterâ€2 inhibitors in heart failure with mildly reduced ejection fraction. ESC Heart Failure, 0, , .	3.1	2
485	Four aces of heart failure therapy: systematic review of established and emerging therapies for heart failure with reduced ejection fraction. Cardiology Plus, 2022, 7, 20-28.	0.7	1

#	Article	IF	Citations
486	Treatment of iron deficiency in patients after acute decompensation: a new target in the treatment of heart failure. Russian Journal of Cardiology, 2022, 27, 4949.	1.4	3
487	Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations. Cardiology Journal, 0, , .	1.2	3
488	Forecasting HeartÂFailure Risk in Diabetes. Journal of the American College of Cardiology, 2022, 79, 2294-2297.	2.8	2
489	Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review. Advances in Therapy, 2022, 39, 3472-3487.	2.9	4
490	Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review. Diabetes Therapy, 2022, 13, 19-34.	2.5	3
491	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35.	2.2	5
492	Clinical Benefits of Sodiumâ€“Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC Asia, 2022, 2, 287-293.	1.5	6
493	A multidisciplinary approach to heart failure care in the hospital: improving the patient journey. Hospital Practice (1995), 0, , .	1.0	0
494	New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. Frontiers in Pharmacology, 0, 13, .	3.5	7
495	Effects of SGLT2 inhibitors on cardiac structure and function. Heart Failure Reviews, 2023, 28, 697-707.	3.9	5
496	Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy. Current Heart Failure Reports, 2022, 19, 191-199.	3.3	2
497	Implementation of Multiple Evidence-Based Heart Failure Therapies. Current Problems in Cardiology, 2022, , 101293.	2.4	0
498	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Frontiers in Endocrinology, 0, 13, .	3.5	6
499	From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients. Drugs, 2022, 82, 949-955.	10.9	11
500	Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. American Heart Journal Plus, 2022, 18, 100154.	0.6	2
501	Future scope and challenges for congestive heart failure: Moving towards development of pharmacotherapy. Canadian Journal of Physiology and Pharmacology, 0, , .	1.4	2
503	Side effects and treatment initiation barriers of sodiumâ€“glucose cotransporter 2 inhibitors in heart failure: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2022, 24, 1625-1632.	7.1	10
504	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. Journal of Diabetes Investigation, 2022, 13, 1472-1488.	2.4	2

#	Article	IF	Citations
505	Left ventricular ejection fraction as the primary heart failure phenotyping parameter. European Journal of Heart Failure, 2022, 24, 1158-1161.	7.1	15
506	Treating Cardiodiabetic Continuum by SGLT2 Inhibitors: From Diabetes Mellitus to Heart Failure. Cardiometabolic Syndrome Journal, 0, 2, .	0.6	0
507	An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations. Diabetes Therapy, 0, , .	2.5	1
508	Improving implementation of evidenceâ€based therapies for heart failure. Clinical Cardiology, 2022, 45, .	1.8	2
509	Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clinical Cardiology, 2022, 45, .	1.8	8
511	In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 0, 8, .	3.0	9
512	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. Endocrinology and Metabolism, 2022, 37, 415-429.	3.0	3
513	Clinical Evidence and Proposed Mechanisms of Sodiumâ€“Glucose CotransporterÂ2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?. Cardiac Failure Review, 0, 8, .	3.0	9
514	Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis. International Journal of Cardiology, 2022, 366, 51-56.	1.7	9
515	A surveyâ€based triage tool to identify patients potentially eligible for referral to an advanced heart failure centre. ESC Heart Failure, 2022, 9, 3643-3648.	3.1	3
516	Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, .		10
517	Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction. Clinical Cardiology, 2022, 45, .	1.8	2
518	Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis. European Journal of Internal Medicine, 2022, 104, 128-130.	2.2	2
521	Los iSGLT2 en la insuficiencia cardiaca. Â¿Sus beneficios pueden extenderse a todo el espectro de la fracciÃ³n de eyecciÃ³n?. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	0
522	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112.	1.2	5
523	Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodiumâ€“glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. European Heart Journal Quality of Care & Clinical Outcomes, 0, , .	4.0	2
524	Cardiovascular protection by SGLT2 inhibitors â€“ Do anti-inflammatory mechanisms play a role?. Molecular Metabolism, 2022, 64, 101549.	6.5	23
525	Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study. Diabetes Care, 2022, 45, 2118-2126.	8.6	12

#	Article	IF	Citations
526	The use of sodium-glucose cotransporter 2 inhibitor in heart failure: The rise of the Roman Empire!. The National Medical Journal of India, 0, 34, 347-350.	0.3	0
527	Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. Cardiac Failure Review, 0, 8, .	3.0	2
528	Medical therapy for heart failure with preserved ejection fraction: Still a minefield, but with new hope. Revista Portuguesa De Cardiologia, 2022, , .	0.5	0
529	Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. Journal of Cardiovascular Development and Disease, 2022, 9, 225.	1.6	3
530	The Diabetic Cardiorenal Nexus. International Journal of Molecular Sciences, 2022, 23, 7351.	4.1	6
532	Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 2022, 24, 2071-2080.	4.4	16
533	Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study. Seminars in Arthritis and Rheumatism, 2022, 56, 152058.	3.4	3
534	Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice. Heart Failure Reviews, 0, , .	3.9	4
535	Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 381-393.	3.3	7
536	Tolerability and safety barriers to sodiumâ€“glucose cotransporter 2 inhibitor initiation in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 1633-1635.	7.1	1
537	SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy. Circulation, 2022, 146, 299-302.	1.6	6
538	Progress in the management of patients with diabetes and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2022, 31, 456-463.	2.0	1
539	Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction. Life, 2022, 12, 1112.	2.4	0
540	Consensus statement on the current pharmacological prevention and management of heart failure. Medical Journal of Australia, 2022, 217, 212-217.	1.7	14
541	Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. International Journal of Molecular Sciences, 2022, 23, 7966.	4.1	8
542	Sodiumâ€glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease. ESC Heart Failure, 0, , .	3.1	1
543	Hospital Diabetes Meeting 2022. Journal of Diabetes Science and Technology, 0, , 193229682211108.	2.2	1
544	Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?. Expert Opinion on Pharmacotherapy, 2022, 23, 1497-1502.	1.8	4

#	Article	IF	Citations
545	Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry. Circulation: Heart Failure, 2022, 15, .	3.9	13
546	Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors. Current Diabetes Reviews, 2022, 19, .	1.3	1
547	2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Canadian Journal of Cardiology, 2022, 38, 1153-1167.	1.7	17
548	Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. Frontiers in Pharmacology, 0, 13, .	3.5	12
549	Sodium Glucose Co-Transporter 2 Inhibitors Improve Renal Congestion and Left Ventricular Fibrosis in Rats With Hypertensive Heart Failure. Circulation Journal, 2022, 86, 2029-2039.	1.6	4
551	Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?. European Heart Journal, 2022, 43, 4754-4757.	2.2	13
553	SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction. Cardiovascular Drugs and Therapy, 2023, 37, 989-996.	2.6	7
554	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€”2022 Update. Endocrine Practice, 2022, 28, 923-1049.	2.1	146
555	Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	6.8	18
556	Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?. Herz, 0, , .	1.1	1
557	Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism. Journal of Cardiovascular Translational Research, 2023, 16, 327-340.	2.4	4
558	Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?. International Journal of Molecular Sciences, 2022, 23, 8631.	4.1	7
559	Effect of mineralocorticoid receptor antagonist at baseline on the efficacy of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology, 2022, 29, e334-e337.	1.8	2
560	SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia, 2022, 65, 2000-2010.	6.3	26
562	The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. Pharmaceutics, 2022, 14, 1730.	4.5	18
563	Latent autoimmune diabetes in adults in China. Frontiers in Immunology, 0, 13, .	4.8	2
564	Use of sodium glucose coâ€transporter 2 inhibitors in acute heart failure: a practical guidance. ESC Heart Failure, 0, , .	3.1	2
565	Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovascular Research, 2023, 118, 3536-3555.	3.8	29

#	Article	IF	Citations
566	Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	6.8	3
567	The Effectiveness of Sodium-Glucose Cotransporter 2ÂInhibitors and Glucagon-like Peptide-1 Receptor AgonistsÂon Cardiorenal Outcomes: Systematic Review andÂMeta-analysis. Canadian Journal of Cardiology, 2022, 38, 1201-1210.	1.7	12
568	The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 2583-2597.	2.4	13
569	Cardiorenal protection of SGLT2 inhibitorsâ€"Perspectives from metabolic reprogramming. EBioMedicine, 2022, 83, 104215.	6.1	26
570	The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. International Immunopharmacology, 2022, 111, 109080.	3.8	28
571	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. IJC Heart and Vasculature, 2022, 42, 101103.	1.1	4
572	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects. Drug Design, Development and Therapy, 0, Volume 16, 2967-2980.	4.3	2
573	Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovascular Diabetology, 2022, 21, .	6.8	19
574	SGLT2 Inhibitors Should Be Considered for All Patients With HeartÂFailure. Journal of the American College of Cardiology, 2022, 80, 1311-1313.	2.8	1
575	Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology, 2022, 80, 1302-1310.	2.8	49
576	SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. Methodist DeBakey Cardiovascular Journal, 2022, 18, 62-72.	1.0	3
577	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure a multinational randomized trial (The EMPULSE Trial). Journal of the Practice of Cardiovascular Sciences, 2022, 8, 77.	0.1	0
578	Herz und Diabetes. Springer Reference Medizin, 2022, , 1-14.	0.0	0
579	Overview of trials from AHA 2021. Global Cardiology Science & Practice, 2021, 2021, .	0.4	0
580	Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 2022, 28, 1956-1964.	30.7	111
581	Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure. European Heart Journal, 2022, 43, 4433-4435.	2.2	2
582	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction. JAMA Cardiology, 2022, 7, 1067.	6.1	12
583	Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. , 0, , .		0

#	Article	IF	Citations
584	Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2022, 11, 5027.	2.4	3
586	SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, The, 2022, 400, 757-767.	13.7	307
587	Efficacy of pharmacologic therapies in patients with acute heart failure: A network meta-analysis. Frontiers in Pharmacology, 0, 13, .	3.5	0
588	Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
589	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2022, 65, 1925-1966.	6.3	273
590	Impact of Worsening Heart Failure on Long-Term Prognosis in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2022, 184, 63-71.	1.6	2
591	New Strategies to Prevent Rehospitalizations for Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 199-212.	0.9	2
592	Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality. Cardiovascular Research, 2023, 119, 1130-1145.	3.8	6
593	â€˜Acute Heart Failureâ€™: Should We Abandon the Term Altogether?. Current Heart Failure Reports, 2022, 19, 425-434.	3.3	3
594	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2022, 45, 2753-2786.	8.6	435
595	HeartÂFailure Drug Treatmentâ€”Inertia,ÂTitration, and Discontinuation. JACC: Heart Failure, 2023, 11, 1-14.	4.1	51
596	The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials. Frontiers in Endocrinology, 0, 13, .	3.5	4
597	Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. Cureus, 2022, , .	0.5	1
598	New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
599	SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	6
600	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. , 0, Publish Ahead of Print, .		0
601	Incident heart failure, arrhythmias and cardiovascular outcomes with sodiumâ€glucose cotransporter 2 (<scp>SGLT2</scp>) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. Diabetes, Obesity and Metabolism, 2023, 25, 602-610.	4.4	17
602	Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain. Journal of Clinical Medicine, 2022, 11, 5199.	2.4	12

#	Article	IF	Citations
603	Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives. Pharmaceutics, 2022, 14, 1964.	4.5	0
604	Patient preferences for newer oral therapies in type 2 diabetes. International Journal of Cardiology, 2023, 371, 526-532.	1.7	4
605	A review of cardiovascular benefits of SGLT2 inhibitors. Medicine (United States), 2022, 101, e30310.	1.0	1
606	Use of Glucose-Lowering Agents in Diabetes and CKD. Kidney International Reports, 2022, 7, 2589-2607.	0.8	7
607	Cost effectiveness analyses of pharmacological treatments in heart failure. Frontiers in Pharmacology, 0, 13, .	3.5	6
608	Diagnosing heart failure with preserved ejection fraction in cardiac amyloidosis or diagnosing cardiac amyloidosis in heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2022, 24, 2387-2389.	7.1	0
609	Diabetes and cardiovascular risk according to sex: An overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. Annales D'Endocrinologie, 2023, 84, 57-68.	1.4	2
610	A 96â€week, doubleâ€blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism, 2023, 25, 293-301.	4.4	7
611	In silicodiscovery of potential sodiumâ€“glucose cotransporter-2 inhibitors from natural products for treatment of heart failure via molecular docking and molecular dynamics simulation approach. Journal of Biomolecular Structure and Dynamics, 2023, 41, 8109-8120.	3.5	5
612	Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk. Heart Failure Clinics, 2022, 18, 645-654.	2.1	3
613	SGLT2 Inhibitors in Heart Failure. Heart Failure Clinics, 2022, 18, 587-596.	2.1	6
614	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 3442-3451.	3.6	7
615	Inhibiting the proximal nephron in acute heart failureÂâ€“Âemerging data on kidney safety and efficacy. European Journal of Heart Failure, 2022, 24, 1853-1855.	7.1	0
616	SGLT2 Inhibitors in Type 2 Diabetes Mellitus. Heart Failure Clinics, 2022, 18, 551-559.	2.1	2
617	Actualization of Positions of Gliflozins in Treatment Algorithms for Patients with Heart Failure: Chronology of Success. I P Pavlov Russian Medical Biological Herald, 2022, 30, 411-421.	0.5	1
618	SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Heart Failure Clinics, 2022, 18, 561-577.	2.1	2
619	Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients. Heart Failure Reviews, 2023, 28, 949-959.	3.9	7
620	SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2022, 18, 579-586.	2.1	3

#	Article	IF	Citations
621	Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender. Current Heart Failure Reports, 2022, 19, 467-475.	3.3	2
622	SGLT2 Inhibitors Are Lifesavers in Heart Failure. Heart Failure Clinics, 2022, 18, xi-xiv.	2.1	0
623	Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 473-489.	2.2	5
624	Reporting and Definition of Kidney Death in Heart Failure Clinical Trials. Current Problems in Cardiology, 2022, 47, 101382.	2.4	0
625	The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney. International Journal of Molecular Sciences, 2022, 23, 11987.	4.1	7
626	Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. European Heart Journal, 2023, 44, 41-50.	2.2	63
627	Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin. Life, 2022, 12, 1663.	2.4	8
628	SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. Biomedicines, 2022, 10, 2458.	3.2	9
629	Ketones: the double-edged sword of SGLT2 inhibitors?. Diabetologia, 2023, 66, 23-32.	6.3	14
630	Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. BMC Health Services Research, 2022, 22, .	2.2	13
631	Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials. Heart Failure Reviews, 2023, 28, 925-936.	3.9	8
632	Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3
633	Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses. Circulation, 2022, 146, 1507-1517.	1.6	18
634	Considerations in the Interpretation of Patient Reported Outcomes in Heart Failure with Reduced and Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, , .	1.7	0
635	One size fits all: The story of SGLT2 inhibitors in heart failure. Med, 2022, 3, 735-739.	4.4	3
636	Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. European Journal of Heart Failure, 2022, 24, 2029-2036.	7.1	11
637	Safety of sodiumâ€“glucose c<scp>otransporter</scp>Â2 inhibitors in Asian typeâ€‰2 diabetes populations. Journal of Diabetes Investigation, 2023, 14, 167-182.	2.4	3
638	A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nature Communications, 2022, 13, .	12.8	9

#	Article	IF	Citations
639	SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. European Journal of Pharmacology, 2022, 936, 175354.	3.5	4
640	Emerging roles of sodiumâ€glucose coâ€transporter inhibitors. The Prescriber, 2022, 33, 11-17.	0.3	0
641	Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2023, 186, 150-155.	1.6	5
642	Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial. Journal of Cardiac Failure, 2023, 29, 33-41.	1.7	8
643	Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists. Structural Heart, 2022, , 100082.	0.6	0
644	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2022, 102, S1-S127.	5.2	246
645	Cardiorenal disease management in type 2 diabetes: An expert consensus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102661.	3.6	1
646	Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
647	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 1957-1974.	1.8	0
648	Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney International, 2022, 102, 990-999.	5.2	78
649	Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction. European Journal of Pharmacology, 2022, 936, 175357.	3.5	6
650	Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. Journal of Kidney Care, 2022, 7, 216-224.	0.1	0
651	Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 869-881.	11.4	15
652	Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet, The, 2022, 400, 1938-1952.	13.7	226
653	Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	6.8	4
654	The Anti-Inflammatory Effect of Novel Antidiabetic Agents. Life, 2022, 12, 1829.	2.4	9
655	Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet, The, 2022, 400, 1788-1801.	13.7	249
656	Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges. European Heart Journal, 0, , .	2.2	0

#	Article	IF	Citations
657	Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. Cardiovascular Diabetology, 2022, 21, .	6.8	3
658	Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. Frontiers in Physiology, 0, 13, .	2.8	1
659	Neighborhood Socioeconomic Disadvantage and Hospitalized Heart Failure Outcomes in the American Heart Association Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2022, 15, .	3.9	10
660	Diabetic cardiomyopathy: a brief summary on lipid toxicity. ESC Heart Failure, 2023, 10, 776-790.	3.1	6
661	Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Diabetes Research and Clinical Practice, 2022, 194, 110161.	2.8	11
662	Risk of hypovolemia associated with sodiumâ€“glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	4
663	Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible. European Heart Journal Supplements, 2022, 24, I153-I159.	0.1	1
664	Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada. BMJ Open Diabetes Research and Care, 2022, 10, e002995.	2.8	6
665	Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation, 2023, 147, 284-295.	1.6	13
666	Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications, 2022, 36, 108352.	2.3	3
667	<scp>Healthâ€related</scp> quality of life outcomes in <scp>PARAGONâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 2264-2274.	7.1	6
669	Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes. American Journal of Cardiology, 2023, 187, 93-99.	1.6	2
670	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist DeBakey Cardiovascular Journal, 2022, 18, 40-53.	1.0	0
671	Lessons from the EMPEROR Preserved. , 2022, 2, 329-330.		0
672	Corrigendum to â€œMechanisms and pharmacotherapy of hypertension associated with type 2 diabetesâ€• [Biochem. Pharmacol. 206 (2022) 115304]. Biochemical Pharmacology, 2023, 207, 115349.	4.4	0
673	The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. , 2023, 14, 46.		9
674	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodiumâ€“Glucose Co-transporter-2 Inhibitors. European Endocrinology, 2022, 18, 106.	1.5	4
675	Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?. Cureus, 2022, , .	0.5	1

#	Article	IF	Citations
676	Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. Frontiers in Pharmacology, 0, 13, .	3.5	1
677	Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. Current Atherosclerosis Reports, 2022, 24, 925-937.	4.8	2
678	The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. Pharmacy (Basel, Switzerland), 2022, 10, 166.	1.6	2
679	Diabetes mellitus type 1 and coronary artery disease with severe systolic heart failure in 25 year-old adult. Diabetes Mellitus, 2022, 25, 514-521.	1.9	0
680	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nature Reviews Endocrinology, 2023, 19, 151-163.	9.6	21
681	Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World Journal of Cardiology, 0, 14, 599-616.	1.5	1
682	Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?. European Heart Journal, 2023, 44, 51-53.	2.2	6
683	The EMPULSE Trial. Intervencni A Akutni Kardiologie, 2022, 21, 174-177.	0.0	0
684	Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews. International Journal of Cardiology, 2022, , .	1.7	1
685	SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Healthcare (Switzerland), 2022, 10, 2356.	2.0	1
686	Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events. JAMA Network Open, 2022, 5, e2243201.	5.9	6
687	Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3
688	Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. Cardiovascular Research, 2023, 118, 3467-3481.	3.8	4
689	Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials. American Journal of Cardiovascular Drugs, 2023, 23, 113-126.	2.2	2
690	Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
691	Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. Cardiosomatics, 2022, 13, 115-123.	0.4	0
692	Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial. American Heart Journal, 2023, 257, 85-92.	2.7	1
693	The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors. Expert Review of Cardiovascular Therapy, 2023, 21, 15-34.	1.5	4

#	Article	IF	Citations
694	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ€”2023. Diabetes Care, 2023, 46, S158-S190.	8.6	156
695	Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women. Journal of the Endocrine Society, 2022, 7, .	0.2	2
697	Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making. American Journal of Medicine, 2023, 136, 260-269.e7.	1.5	10
698	Cardiovascular Alterations and Structural Changes in the Setting of Chronic Kidney Disease: a Review of Cardiorenal Syndrome Type 4. SN Comprehensive Clinical Medicine, 2023, 5, .	0.6	2
699	Polypharmacy in Older People with Heart Failure: Roles of the Geriatrician and Pharmacist. Cardiac Failure Review, 0, 8, .	3.0	1
700	The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice. Cardiology, 2023, 148, 27-37.	1.4	3
701	Getting ahead of the game: in-hospital initiation of HFrEF therapies. European Heart Journal Supplements, 2022, 24, L38-L44.	0.1	3
702	Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. Frontiers in Endocrinology, 0, 13, .	3.5	3
703	The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest. Life, 2022, 12, 2062.	2.4	5
704	Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. , 2023, 242, 108330.		5
706	Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. ESC Heart Failure, 2023, 10, 1555-1569.	3.1	3
707	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. European Heart Journal Supplements, 2022, 24, L10-L19.	0.1	6
708	Aiming at harmony. Comparing and contrasting International HFrEF Guidelines. European Heart Journal Supplements, 2022, 24, L20-L28.	0.1	7
709	New Insights into the Use of Empagliflozinâ€”A Comprehensive Review. Biomedicines, 2022, 10, 3294.	3.2	6
710	Targeting the â€˜vulnerableâ€™ periodÂâ€“Âfirst 3â€“6Âmonths after an acute heart failure admissionÂâ€“Âthe light gets brighter. European Journal of Heart Failure, 2023, 25, 30-34.	7.1	5
711	Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?. Revista Romana De Cardiologie, 2022, 32, 167-173.	0.1	1
712	New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. Updates in Hypertension and Cardiovascular Protection, 2023, , 337-349.	0.1	0
713	Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute HeartÂFailureÂHospitalization. JACC: Heart Failure, 2023, 11, 596-606.	4.1	4

#	Article	IF	Citations
714	Costâ€effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. European Journal of Heart Failure, 0, , .	7.1	3
715	Use of <scp>patientâ€reported</scp> outcomes in heart failure: from clinical trials to routine practice. European Journal of Heart Failure, 2023, 25, 139-151.	7.1	16
716	Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. Vascular Medicine, 2023, 28, 62-76.	1.5	4
717	Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Annals of Internal Medicine, 2023, 176, 381-387.	3.9	35
718	SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nature Reviews Cardiology, 2023, 20, 443-462.	13.7	38
719	Acute heart failure after nonâ€cardiac surgery: incidence, phenotypes, determinants and outcomes. European Journal of Heart Failure, 2023, 25, 347-357.	7.1	7
720	Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure. Kidney and Dialysis, 2023, 3, 56-72.	1.0	3
721	Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. Journal of Cardiovascular Pharmacology, 2023, 81, 4-14.	1.9	11
722	Albuminuria and HeartÂFailure. Journal of the American College of Cardiology, 2023, 81, 270-282.	2.8	15
723	Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clinical Research in Cardiology, 2023, 112, 1044-1055.	3.3	5
724	Little at a time: trying to understand the battery of benefits of sodiumâ€“glucose contransporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2023, 25, 235-237.	7.1	2
725	Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction. Drugs in Context, 0, 12, 1-14.	2.2	1
726	Control of Blood Glucose and Cardiovascular Risk Profile. Updates in Hypertension and Cardiovascular Protection, 2023, , 451-469.	0.1	0
727	Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapyâ€"A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. Journal of Clinical Medicine, 2023, 12, 379.	2.4	4
728	Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?. Diabetes and Metabolism, 2023, 49, 101419.	2.9	9
729	Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. European Journal of Medical Research, 2022, 27, .	2.2	6
730	Consider this SGLT2 inhibitor for patients with HF with preserved ejection fraction. , 2022, 71, .		0
731	Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. Medicine (United States), 2022, 101, e32489.	1.0	1

#	Article	IF	Citations
732	Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis. Cardiology in Review, 2024, 32, 114-123.	1.4	4
733	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	11
734	Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods. ESC Heart Failure, 2023, 10, 1231-1241.	3.1	5
735	SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. Biomedicines, 2023, 11, 279.	3.2	7
736	Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Frontiers in Endocrinology, 0, 14, .	3.5	6
737	Impact of baseline kidney function on the effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors on kidney and heart failure outcomes: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2023, 25, 1341-1350.	4.4	7
738	Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. Canadian Journal of Kidney Health and Disease, 2023, 10, 205435812211505.	1.1	3
739	Management of Heart Failure With Reduced Ejection Fraction. Current Problems in Cardiology, 2023, 48, 101596.	2.4	5
740	Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 343-352.	3.0	2
741	Use of sodiumâ€“glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation. CMAJ Open, 2023, 11, E101-E109.	2.4	3
742	Worsening HeartÂFailure: Nomenclature, Epidemiology, and Future Directions. Journal of the American College of Cardiology, 2023, 81, 413-424.	2.8	50
743	Kidney Drug Transporters in Pharmacotherapy. International Journal of Molecular Sciences, 2023, 24, 2856.	4.1	5
744	Sodium-Glucose Cotransporter-2ÂInhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Problems in Cardiology, 2023, 48, 101597.	2.4	4
745	Research Progress of SGLT2 Inhibitors in the Treatment of Heart Failure Complicated with Atrial Fibrillation. Advances in Clinical Medicine, 2023, 13, 2632-2642.	0.0	0
746	Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes and Endocrinology,the, 2023, 11, 233-241.	11.4	8
747	Time to Benefit With Sotagliflozin in Patients With Worsening HeartÂFailure. Journal of the American College of Cardiology, 2023, 81, 1546-1549.	2.8	4
748	Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12â€week, multicentre, randomized, doubleâ€blind, placeboâ€controlled, phase 2 trial. Diabetes, Obesity and Metabolism, 2023, 25, 2096-2104.	4.4	4
749	Regional management of worsening heart failure: rationale and design of the CHAINâ€HF registry. ESC Heart Failure, 2023, 10, 2074-2083.	3.1	2

#	Article	IF	Citations
750	Potential global impact of <scp>sodiumâ€“glucose</scp> cotransporterâ€2 inhibitors in heart failure. European Journal of Heart Failure, 2023, 25, 999-1009.	7.1	9
751	Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Review of Clinical Pharmacology, 2023, 16, 149-160.	3.1	5
752	Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis. American Heart Journal Plus, 2023, 26, 100261.	0.6	7
753	Medication-Attributable Adverse EventsÂin HeartÂFailure Trials. JACC: Heart Failure, 2023, 11, 425-436.	4.1	1
754	Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?. Archives of Medical Science, 2023, 19, 528-531.	0.9	0
755	Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction. American Journal of Medicine, 2023, , .	1.5	0
756	Letter by Sawami et al Regarding Article, â€œEffects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)â€• Circulation, 2023, 147, .	1.6	1
757	Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	2
758	Pharmacotherapy treatment patterns at hospital discharge and clinical outcomes among patients with heart failure with reduced ejection fraction. Chronic Diseases and Translational Medicine, 2023, 9, 154-163.	1.2	0
759	Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors. Life, 2023, 13, 497.	2.4	5
760	Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium. Cardiovascular Drugs and Therapy, 0, , .	2.6	3
761	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes, Obesity and Metabolism, 2023, 25, 1646-1657.	4.4	10
762	Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety. Cureus, 2023, , .	0.5	1
763	Evaluation of heart failure admission as a surrogate for mortality in randomized clinical trials: A metaâ€analysis. European Journal of Clinical Investigation, 2023, 53, .	3.4	2
764	SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. Medicina (Lithuania), 2023, 59, 388.	2.0	4
765	The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacy, 2023, 45, 547-555.	2.1	3
766	Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Annals of Pharmacotherapy, 2023, 57, 1291-1301.	1.9	1
767	The renaissance of one-dimensional carbon nanotubes in tissue engineering. Nano Today, 2023, 49, 101784.	11.9	17

#	Article	IF	Citations
768	Recency of HeartÂFailure Hospitalization, Outcomes, and the Effect of Empagliflozin. JACC: Heart Failure, 2023, 11, 702-712.	4.1	1
769	The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. Current Pharmaceutical Design, 2023, 29, 481-493.	1.9	1
770	Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Clinical and Laboratory Variables in Heart Failure Patients with Reduced Left Ventricular Ejection Fraction in a Latin American Hospital: A Retrospective Study. Hearts, 2023, 4, 20-27.	0.9	0
771	Sacubitrilâ€"valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis. Frontiers in Pharmacology, 0, 14, .	3.5	0
772	SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. Journal of Internal Medicine, 2023, 293, 550-558.	6.0	0
773	Sotagliflozin, a dual sodiumâ€glucose coâ€transporterâ€1 and sodiumâ€glucose coâ€transporterâ€2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno <scp>T1</scp> Risk Engine in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 1874-1882.	4.4	4
774	Proposed New Conceptualization for Definition of DecompensatedÂHF. JACC: Heart Failure, 2023, 11, 368-371.	4.1	2
775	Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation, 2023, 147, 1067-1078.	1.6	3
776	Acute Cardiorenal Syndrome: An Update. Cardiology in Review, 0, Publish Ahead of Print, .	1.4	0
777	Identifying the patient with heart failure to be treated with vericiguat. Current Medical Research and Opinion, 2023, 39, 661-669.	1.9	1
778	Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. Journal of Cardiovascular Development and Disease, 2023, 10, 114.	1.6	0
779	SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis. Indian Heart Journal, 2023, 75, 122-127.	0.5	9
780	Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure. Biomedicines, 2023, 11, 876.	3.2	1
781	Regulated cell death pathways in cardiomyopathy. Acta Pharmacologica Sinica, 2023, 44, 1521-1535.	6.1	12
782	Early Initiation of Dapagliflozin during Hospitalization for Acute Heart Failure is Associated with a Shorter Hospital Stay. Internal Medicine, 2023, , .	0.7	0
783	Efficacy of sodiumâ€"glucose cotransporter 2 inhibitors and angiotensin <scp>receptorâ€"neprilysin</scp> inhibitors for heart failure in black patients: a systematic review and <scp>metaâ€analysis</scp> of randomized controlled trials. European Journal of Heart Failure, 2023, 25, 591-593.	7.1	0
784	Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction. Journal of Clinical Medicine, 2023, 12, 2410.	2.4	2
785	SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. International Journal of Heart Failure, 2023, 5, 82.	2.7	14

#	Article	IF	Citations
786	SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Metaâ€analysis of randomized clinical trials. Journal of Cardiovascular Electrophysiology, 2023, 34, 1277-1285.	1.7	14
787	Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization. Expert Opinion on Pharmacotherapy, 2023, 24, 705-713.	1.8	0
788	Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review. American Journal of Health-System Pharmacy, 0, , .	1.0	0
789	Systematic review of sodiumâ€glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failureâ€related events. ESC Heart Failure, 2023, 10, 1499-1530.	3.1	8
790	Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers. Clinical Drug Investigation, 2023, 43, 241-250.	2.2	0
791	The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 858-868.	4.5	0
792	Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. , 2023, , 337-363.		0
793	Event Adjudication Is Unnecessary in Blinded Trials and May Be Detrimental. JACC: Heart Failure, 2023, 11, 422-424.	4.1	0
794	Evolving Diagnostic and Management Advances in Coronary Heart Disease. Life, 2023, 13, 951.	2.4	3
795	Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Critical Care Medicine, 2023, 51, 1074-1085.	0.9	2
796	Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review. Cureus, 2023, , .	0.5	0
797	Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. Journal of Clinical Medicine, 2023, 12, 2824.	2.4	1
798	A review of current key guidelines for managing highâ€risk patients with diabetes and heart failure and future prospects. Diabetes, Obesity and Metabolism, 2023, 25, 33-47.	4.4	0
799	Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Cardiosomatics, 2023, 13, 198-205.	0.4	0
800	Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins. Current Hypertension Reports, 2023, 25, 91-106.	3.5	2
801	CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. WiadomoÅ›ci Lekarskie, 2023, 76, 645-650.	0.3	0
802	Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Leads to a Shorter Hospital Stay in Patients With Acute Decompensated Heart Failure. Circulation Reports, 2023, , .	1.0	0
803	Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. Life, 2023, 13, 1024.	2.4	1

#	Article	IF	Citations
804	Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. Journal of Cardiovascular Pharmacology and Therapeutics, 2023, 28, 107424842311622.	2.0	0
805	Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease. Expert Opinion on Pharmacotherapy, 2023, 24, 935-945.	1.8	1
806	The Role of SGLT2 Inhibitors in Cardiovascular Management. Cardiology in Review, 0, Publish Ahead of Print, .	1.4	0
807	Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art. Iberoamerican Journal of Medicine, 2023, 5, 68-77.	0.2	1
808	Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial. Circulation, 2023, 147, 1654-1669.	1.6	15
809	2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2023, 81, 1835-1878.	2.8	74
810	Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide. Current Cardiology Reports, 0, , .	2.9	0
811	Pharmacotherapy of heart failure with reduced ejection fraction: heart failure basic therapy and an episode of decompensation. Kardiologiya, 2023, 63, 66-76.	0.7	1
812	Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. European Heart Journal Supplements, 2023, 25, C309-C315.	0.1	3
814	Sodiumâ€“glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 444-452.	3.0	2
815	Canadian Cardiovascular Society-Canadian Heart Failure Society Focused Clinical Practice Update of Patients With Differing Heart Failure Phenotypes. Canadian Journal of Cardiology, 2023, 39, 1030-1040.	1.7	7
816	A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors. Current Problems in Cardiology, 2023, 48, 101817.	2.4	1
817	Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction. Experimental and Molecular Medicine, 2023, 55, 1174-1181.	7.7	2
819	Chronic heart failure: the role of di vericiguat. European Heart Journal Supplements, 2023, 25, C316-C318.	0.1	3
820	The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Review of Endocrinology and Metabolism, 2023, 18, 271-282.	2.4	3
821	Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus. Current Drug Targets, 2023, 24, 648-661.	2.1	1
822	Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2024, 137, S9-S24.	1.5	1
823	Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction. Journal of the American Heart Association, 2023, 12, .	3.7	0

#	Article	IF	Citations
824	Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	1
825	Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. European Journal of Heart Failure, 2023, 25, 936-955.	7.1	20
826	Stabilization of kidney function and reduction in heart failure events with sodiumâ€glucose coâ€transporter 2 inhibitors: A metaâ€analysis and metaâ€regression analysis. Diabetes, Obesity and Metabolism, 0, , .	4.4	0
827	Sodium-glucose cotransporter 2 inhibitors and the treatment of acute coronary syndrome: Does the use make sense?. , 2023, 2, 81-86.		0
828	Uptitrating Treatment After HeartÂFailure Hospitalization Across theÂSpectrum of LeftÂVentricular EjectionÂFraction. Journal of the American College of Cardiology, 2023, 81, 2131-2144.	2.8	16
829	Safety, tolerability and efficacy of upâ€titration of guidelineâ€directed medical therapies for acute heart failure in elderly patients: A subâ€analysis of the <scp>STRONGâ€HF</scp> randomized clinical trial. European Journal of Heart Failure, 2023, 25, 1145-1155.	7.1	7
830	Organizing medical care for patients with chronic heart failure in Russia regions with a low population density. Profilakticheskaya Meditsina, 2023, 26, 102.	0.6	0
831	Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction. Drugs, 2023, 83, 747-759.	10.9	2
832	Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2023, 17, 102804.	3.6	1
833	A Critical View over the Newest Antidiabetic Molecules in Light of Efficacyâ€”A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2023, 24, 9760.	4.1	4
834	When Should We Start Sodiumâ€“Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention. European Cardiology Review, 0, 18, .	2.2	0
835	Specialized heart failure clinics versus primary care: Extended registry-based follow-up of the NorthStar trial. PLoS ONE, 2023, 18, e0286307.	2.5	2
836	Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes. Journal of Clinical Medicine, 2023, 12, 3925.	2.4	3
837	Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes. Cardiovascular Drugs and Therapy, 0, , .	2.6	6
838	POINT: Should New Drug Development in Heart Failure Focus on Patients Discharged From an Acute Heart Failure Admission? Lessons From Recent Studies. Journal of Cardiac Failure, 2023, , .	1.7	1
839	COUNTERPOINT: The Seductive Trap of Relying on Exaggerated Effects in Short-Term Heart Failure Trials to Predict Benefits and Risks in Patients with a Long-Term Disease. Journal of Cardiac Failure, 2023, , .	1.7	0
840	Cost Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Compared with Mineralocorticoid Receptor Antagonists among Patients with Heart Failure and a Reduced Ejection Fraction. Cardiovascular Innovations and Applications, 2023, 8, .	0.3	0
841	Opportunities and Achievement of Medication Initiation Among Inpatients With HeartÂFailure With Reduced EjectionÂFraction. JACC: Heart Failure, 2023, 11, 918-929.	4.1	2

#	Article	IF	Citations
842	Expanded use of sodiumâ€glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction. Pharmacotherapy, 2023, 43, 950-962.	2.6	0
843	Clinician challenges to evidenceâ€based prescribing for heart failure and reduced ejection fraction: A qualitative evaluation. Journal of Evaluation in Clinical Practice, 2023, 29, 1363-1371.	1.8	0
844	Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across VariousÂPatient Populations. Journal of the American College of Cardiology, 2023, 81, 2377-2387.	2.8	16
845	Improving heart failure outcomes with sodiumâ€glucose cotransporter 2 inhibitors in different patient groups. Diabetes, Obesity and Metabolism, 0, , .	4.4	1
846	Critical Reading of cardiovascular trials with neutral or negative results. European Heart Journal, 2023, 44, 4230-4232.	2.2	1
847	What do Spanish registries report about worsening events in chronic heart failure? Needs and challenges. Expert Review of Cardiovascular Therapy, 2023, 21, 473-482.	1.5	0
848	Insulin resistance is associated with subclinical myocardial dysfunction and reduced functional capacity in heart failure with preserved ejection fraction. Journal of Cardiology, 2024, 83, 100-104.	1.9	1
849	Benefits of dapagliflozin in the whole spectrum of heart failure in clinical practice: the RICA registry. Future Cardiology, 2023, 19, 323-332.	1.2	3
850	Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice. Future Cardiology, 2023, 19, 343-351.	1.2	2
851	Inflammation as a therapeutic target in heart failure with preserved ejection fraction. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	1
852	Allâ€cause mortality and cardiovascular outcomes with <scp>sodiumâ€glucose</scp> Coâ€transporter 2 inhibitors, glucagonâ€like peptideâ€1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 2897-2909.	4.4	5
853	Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2023, 25, 776-791.	7.1	33
854	How to Manage HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2023, 11, 619-636.	4.1	10
855	Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis. Cardiovascular Endocrinology and Metabolism, 2023, 12, .	1.1	2
856	Positive Airway Pressure Adherence and Health Care Resource Utilization in Patients With Obstructive Sleep Apnea and Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2023, 12, .	3.7	5
857	Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 0, , .	7.1	3
858	Acute heart failure is a remittingâ€“relapsing disorder and not a step towards advanced heart failure: Implications for decongestion therapy. European Journal of Heart Failure, 0, , .	7.1	1
859	Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression. Diabetes Care, 2023, 46, 1300-1310.	8.6	8

#	Article	IF	Citations
860	Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nature Reviews Cardiology, 2023, 20, 812-829.	13.7	14
861	Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failureâ€"Current Evidence in Special Populations. Life, 2023, 13, 1256.	2.4	2
862	Sodiumâ€"glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. European Heart Journal, 2023, 44, 2216-2230.	2.2	8
863	Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. Contemporary Cardiology, 2023, , 1043-1070.	0.1	0
864	Heart Failure and Cardiac Dysfunction in Diabetes. Contemporary Cardiology, 2023, , 747-781.	0.1	0
865	Predicting and preventing heart failure in type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2023, 11, 607-624.	11.4	4
866	Systematic Review of the Economic Evaluation of Sodiumâ€"Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure. Clinical Drug Investigation, 2023, 43, 463-474.	2.2	0
867	Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review. Cardiovascular Diabetology, 2023, 22, .	6.8	9
868	Letter to the Editor: Latest FDA Approved Drug Sotagliflozin (Inpefa): A Glance at its Prospectives for Heart Failure. Current Problems in Cardiology, 2023, 48, 101897.	2.4	0
869	SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes. IScience, 2023, 26, 107260.	4.1	2
870	Exploring the comparative cardiovascular death benefits of sodiumâ€"glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring. Frontiers in Endocrinology, 0, 14, .	3.5	3
871	Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease. Current Pharmaceutical Design, 2023, 29, 1844-1862.	1.9	2
872	Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction. Journal of Cardiovascular Medicine, 2023, 24, 537-543.	1.5	1
873	SGLT1: A Potential Drug Target for Cardiovascular Disease. Drug Design, Development and Therapy, 0, Volume 17, 2011-2023.	4.3	4
874	Sodiumâ€"Glucose Cotransporter-2 Inhibitors: An Old Medication With New Indication in Heart Failure With Preserved Ejection Fraction. Journal for Nurse Practitioners, 2023, 19, 104716.	0.8	0
875	Realâ€world use of sodiumâ€"glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the <scp>Swedish</scp> Heart Failure Registry. European Journal of Heart Failure, 2023, 25, 1648-1658.	7.1	10
876	So Much to Say on the Best of What's Around Regarding Sodiumâ€Glucose Cotransporterâ€2 Inhibitors in Acute Myocardial Infarction. Journal of the American Heart Association, 2023, 12, .	3.7	0
877	Effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors by background cardiovascular medications: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2023, 25, 3020-3029.	4.4	1

#	Article	IF	Citations
878	State of the art in childhood nephrotic syndrome: concrete discoveries and unmet needs. Frontiers in Immunology, 0, 14, .	4.8	4
879	Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?. , 2023, 2, 705-707.		3
880	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure. Korean Circulation Journal, 2023, 53, 425.	1.9	4
881	Differential effects of sodiumâ€“glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a doseâ€“response meta-analysis involving 10 randomized clinical trials and 71 553 individuals. European Journal of Endocrinology, 2023, 189, S17-S25.	3.7	4
882	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure. International Journal of Heart Failure, 2023, 5, 127.	2.7	1
883	Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study. Cardiovascular Diabetology, 2023, 22, .	6.8	3
884	Heart Failure with Preserved Left Ventricular Ejection Fraction: A Complex Conundrum Simply Not Limited to Diastolic Dysfunction. Cardiovascular Therapeutics, 2023, 2023, 1-18.	2.5	2
885	Association between systemic inflammatory response index and left ventricular remodeling and systolic dysfunction in atrial fibrillation patients. BMC Cardiovascular Disorders, 2023, 23, .	1.7	2
886	Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study. Cardiovascular Diabetology, 2023, 22, .	6.8	1
887	Development and validation of a prediction model based on machine learning algorithms for predicting the risk of heart failure in middleâ€aged and older US people with prediabetes or diabetes. Clinical Cardiology, 2023, 46, 1234-1243.	1.8	2
888	State-of-the-art methodologies used in preclinical studies to assess left ventricular diastolic and systolic function in mice, pitfalls and troubleshooting. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
889	Driving force of deteriorated cellular environment in heart failure: Metabolic remodeling. Clinics, 2023, 78, 100263.	1.5	0
890	What Difference Does a Day Make?. JACC: Heart Failure, 2023, 11, 890-892.	4.1	0
891	Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events. JACC: Heart Failure, 2023, 11, 879-889.	4.1	5
892	What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence. American Journal of Hypertension, 2024, 37, 1-14.	2.0	2
893	Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial. Journal of Cardiac Failure, 2023, , .	1.7	0
894	The Impact of Pharmacotherapy for Heart Failure on Oxidative Stressâ€”Role of New Drugs, Flozins. Biomedicines, 2023, 11, 2236.	3.2	1
895	Kidney Considerations in Pediatric Obesity. Current Obesity Reports, 2023, 12, 332-344.	8.4	2

#	Article	IF	Citations
896	Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials. Heart Failure Reviews, 0, , .	3.9	0
897	Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?. Expert Review of Clinical Pharmacology, 2023, 16, 771-774.	3.1	1
898	Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure. JAMA Network Open, 2023, 6, e2330754.	5.9	1
899	Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure. American Journal of Cardiovascular Drugs, 0, , .	2.2	0
900	2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal, 2023, 44, 4043-4140.	2.2	88
901	Baseline characteristics of patients enrolled in the <scp>EMPACTâ€MI</scp> trial. European Journal of Heart Failure, 0, , .	7.1	1
902	The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials. Acta Cardiologica, 0, , 1-10.	0.9	1
903	Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm. PeerJ, 0, 11, e15647.	2.0	0
904	Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitor Use in Acute Heart Failure Hospitalizations Complicated by Acute Kidney Injury. Kidney360, 2023, , .	2.1	1
905	Cardiovascular efficacy and safety of antidiabetic agents: A network metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2023, 25, 3560-3577.	4.4	3
906	Myocardial Metabolic Reprogramming in HFpEF. Journal of Cardiovascular Translational Research, 2024, 17, 121-132.	2.4	1
907	Association of SGLTâ€2 Inhibitors With Treatment Satisfaction and Diabetesâ€Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes. Journal of the American Heart Association, 0, , .	3.7	0
908	Diabetic Kidney Disease: Goals for Management, Prevention, and Awareness. Encyclopedia, 2023, 3, 1145-1156.	4.5	0
909	Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effectâ€"What Is New in 2023?. Endocrines, 2023, 4, 630-655.	1.0	1
910	Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. European Heart Journal, 2023, 44, 3640-3651.	2.2	5
911	SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. Journal of Cardiovascular Development and Disease, 2023, 10, 322.	1.6	0
912	2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2023, 44, 3627-3639.	2.2	194
913	Mineralocorticoid receptor antagonists with sodiumâ€"glucose co-transporter-2 inhibitors in heart failure: a meta-analysis. European Heart Journal, 2023, 44, 3686-3696.	2.2	7

#	Article	IF	Citations
914	Sotagliflozin for Heart Failure: What We Know About Trials and Mechanisms. Journal of Cardiac Failure, 2023, , .	1.7	0
915	Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?. Cardiology Clinics, 2023, 41, 511-524.	2.2	0
916	Recent successes in heart failure treatment. Nature Medicine, 2023, 29, 2424-2437.	30.7	4
917	Implementing Guideline-Directed MedicalÂTherapy for HeartÂFailure. Journal of the American College of Cardiology, 2023, 82, 529-543.	2.8	6
918	Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Frontiers in Immunology, 0, 14, .	4.8	2
919	The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Annals of Pharmacotherapy, 2024, 58, 506-513.	1.9	0
920	Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Global Heart, 2023, 18, 45.	2.3	1
921	Gaps in Modern Heart Failure and Chronic Kidney Disease Research. European Cardiology Review, 0, 18, .	2.2	0
923	From Pump to Periphery: the Graded Benefit of SGLT2 Inhibitors in HFrEF and Progressive Vascular Disease. Journal of Cardiac Failure, 2023, 29, 1355-1357.	1.7	0
924	A vesefunkciÃ³ hatÃ¡sa a gyÃ³gyszeres terÃ¡pia optimalizÃ¡lÃ¡sÃ¡ra Ã©s a mortalitÃ¡sra csÃ¶kkent ejekciÃ³s frakciÃ³jÃº szÃvelÃ©gtelensÃ©gben. Orvosi Hetilap, 2023, 164, 1387-1396.	0.4	0
925	conTemporary reflectiOns regarding heart Failure manaGEmenT â€“ How to ovERcome the PorTuguese barriers (TOGETHER-PT). Revista Portuguesa De Cardiologia, 2023, , .	0.5	1
926	Heart Failure: Recent Advances and Breakthroughs. Disease-a-Month, 2024, 70, 101634.	1.1	0
927	SGLT2 inhibitors; suggested mechanism of actions in supporting post-myocardial infarction patients. Future Cardiology, 2023, 19, 419-422.	1.2	0
928	Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. European Heart Journal, 0, , .	2.2	1
930	Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality. Cureus, 2023, , .	0.5	0
931	The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status. International Journal of Molecular Sciences, 2023, 24, 14243.	4.1	1
932	Racial, ethnic and regional differences in the effect of sodiumâ€“glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials. Journal of the Royal Society of Medicine, 0, , .	2.0	3
933	SGLT2 inhibitors: an evidence-based update on cardiovascular implications. Expert Opinion on Investigational Drugs, 2023, 32, 839-847.	4.1	5

#	Article	IF	Citations
934	Recurrent Events in Cardiovascular Trials. Journal of the American College of Cardiology, 2023, 82, 1445-1463.	2.8	1
935	Metaâ€analysis of Association between Newer Glucoseâ€Lowering Drugs and Risk of Parkinson's Disease. Movement Disorders Clinical Practice, 2023, 10, 1659-1665.	1.5	1
936	1+2 Might Be >2. JACC: Heart Failure, 2024, 12, 222-225.	4.1	0
937	Combination therapy with kidney protective therapies: optimizing the benefits?. Current Opinion in Nephrology and Hypertension, 0, , .	2.0	0
938	SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials. Medicine (United States), 2023, 102, e34693.	1.0	2
939	Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2023, 325, H1210-H1222.	3.2	2
940	Part I: <scp>PSAP Live</scp>: Updates from 2022 <scp>Book</scp> 1 (<scp>Cardiology</scp>). JACCP Journal of the American College of Clinical Pharmacy, 2023, 6, 1163-1169.	1.0	0
942	Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study. BMC Cardiovascular Disorders, 2023, 23, .	1.7	0
943	Characteristics of the Latest Therapeutic Agent for Diabetes. Journal of Korean Diabetes, 2023, 24, 148-153.	0.3	0
944	Updates on New Therapies for Patients with CKD. Kidney International Reports, 2024, 9, 16-28.	0.8	1
945	Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
946	Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection. Cardiovascular Drugs and Therapy, 0, , .	2.6	1
947	Cardiometabolic effect of sodium and glucosa cotransporter inhibitors type 2. , 0, 3, 563.		0
948	SGLT inhibitors for improving Healthspan and lifespan. Progress in Cardiovascular Diseases, 2023, 81, 2-9.	3.1	1
949	Acute heart failure: current pharmacological treatment and perspectives. European Heart Journal, 2023, 44, 4634-4649.	2.2	3
951	Adverse events and drugâ€“drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure. Expert Review of Cardiovascular Therapy, 2023, 21, 803-816.	1.5	0
952	The current best drug treatment for hypertensive heart failure with preserved ejection fraction. European Journal of Internal Medicine, 2024, 120, 3-10.	2.2	2
954	Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodiumâ€glucose cotransporter 2 inhibitors? A correlation metaâ€analysis. Diabetes, Obesity and Metabolism, 2024, 26, 392-395.	4.4	0

#	Article	IF	Citations
956	Managing heart failure in diabetics with dual acting Sotagliflozin- A review. Health Sciences Review, 2023, , 100130.	1.5	0
957	New insights in acute heart failure. Presse Medicale, 2024, 53, 104184.	1.9	1
958	Heart failure with preserved ejection fraction: New challenges and new hopes. Presse Medicale, 2024, 53, 104185.	1.9	1
959	Utilization of SGLT-2 Inhibitors in Congestive Heart Failure Management. Advanced Journal of Graduate Research, 2023, 14, 3-8.	0.5	0
960	Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases. Current Cardiology Reports, 0, , .	2.9	0
961	Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model. Health Economics Review, 2023, 13, .	2.0	0
962	UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE. BMC Nephrology, 2023, 24, .	1.8	1
963	Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Cardiovascular Diabetology, 2023, 22, .	6.8	1
964	New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events. Journal of Clinical Medicine, 2023, 12, 6956.	2.4	1
965	Endpoint adjudication in cardiovascular clinical trials. European Heart Journal, 2023, 44, 4835-4846.	2.2	1
966	Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c. Journal of the American College of Cardiology, 2023, 82, 1842-1851.	2.8	1
967	Sotagliflozin Efficacy Irrespective ofÂHemoglobin A1c Level. Journal of the American College of Cardiology, 2023, 82, 1852-1853.	2.8	0
968	Sodiumâ€“glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. European Journal of Preventive Cardiology, 0, , .	1.8	3
969	Diabetes Mellitus in Acute Coronary Syndrome. Life, 2023, 13, 2226.	2.4	0
970	Protective effect of canagliflozin on post-resuscitation myocardial function in a rat model of cardiac arrest. Intensive Care Medicine Experimental, 2023, 11, .	1.9	0
971	Acute Heart Failure Is a Malignant Process: But We Can Induce Remission. Journal of the American Heart Association, 2023, 12, .	3.7	1
972	Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review. Cardiovascular Diabetology, 2023, 22, .	6.8	2
973	Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2024, 10, 147-157.	3.0	0

#	Article	IF	Citations
974	Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis. Heart Failure Reviews, 2024, 29, 207-217.	3.9	0
975	Evolution of economic burden of heart failure by ejection fraction in newly diagnosed patients in Spain. BMC Health Services Research, 2023, 23, .	2.2	0
976	Novel pharmacological interventions for diabetic kidney disease. Current Opinion in Nephrology and Hypertension, 2024, 33, 13-25.	2.0	0
977	Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation:ÂA systematic review and metaâ€analysis of randomized controlled trials. PACE - Pacing and Clinical Electrophysiology, 0, , .	1.2	0
978	Inflammation in acute heart failure. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
979	Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?. Expert Opinion on Emerging Drugs, 2023, 28, 217-226.	2.4	0
980	The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF). European Journal of Pharmacology, 2023, 961, 176179.	3.5	1
982	Underrepresentation of Women in Reduced Ejection Heart Failure Clinical Trials with Improved Mortality or Hospitalization. , 2023, , 100743.		0
983	Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology, 2024, 9, 144.	6.1	1
984	The Ketogenic Effect of SGLT-2 Inhibitorsâ€"Beneficial or Harmful?. Journal of Cardiovascular Development and Disease, 2023, 10, 465.	1.6	0
985	Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients. Frontiers in Endocrinology, 0, 14, .	3.5	1
986	Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis. Frontiers in Pharmacology, 0, 14, .	3.5	0
987	Natriuretic peptide testing strategies in heart failure: A 2023 update. Advances in Clinical Chemistry, 2023, , .	3.7	0
989	Rationale and design of the <scp>ESC</scp> Heart Failure <scp>III</scp> RegistryÂâ€"ÂImplementation and discovery. European Journal of Heart Failure, 2023, 25, 2316-2330.	7.1	2
990	Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure. Annals of Pharmacotherapy, 0, , .	1.9	1
991	The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis. PLoS ONE, 2023, 18, e0295059.	2.5	0
992	Association of SGLT2is with cardiovascular and reproductive diseases: a meta-analysis based on 14 large-scale randomized trials. Endocrine, 0, , .	2.3	1
993	Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus. Scientific Reports, 2023, 13, .	3.3	0

#	Article	IF	Citations
994	Medical Management and Device-Based Therapies in Chronic Heart Failure. , 2023, 2, 101206.		0
995	Heart Failure Guideline Directed Medical Therapy: Which One and When?. Cardiovascular Innovations and Applications, 2023, 8, .	0.3	0
996	Standardized Definitions for Evaluation ofÂAcute Decompensated HeartÂFailureÂTherapies. JACC: Heart Failure, 2024, 12, 1-15.	4.1	0
998	Chronic heart failure with reduced EF: A decade of major pharmacological innovations. Presse Medicale, 2024, 53, 104219.	1.9	1
999	Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations. Heart International, 2023, 17, 12.	1.4	0
1000	9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetesâ€”2024. Diabetes Care, 2024, 47, S158-S178.	8.6	11
1001	Effect of the dual sodiumâ€glucose coâ€transporterâ€1 and â€2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2024, 26, 710-720.	4.4	0
1002	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ€”2024. Diabetes Care, 2024, 47, S179-S218.	8.6	8
1003	Congestion in Heart Failure: From the Secret of a Mummy to Todayâ€™s Novel Diagnostic and Therapeutic Approaches: A Comprehensive Review. Journal of Clinical Medicine, 2024, 13, 12.	2.4	1
1004	A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus. European Journal of Pharmaceutical Sciences, 2024, 192, 106644.	4.0	0
1005	Value Judgment of SGLT1/SGLT2 Inhibitors in the Prevention and Treatment of Heart Failure. Advances in Clinical Medicine, 2023, 13, 18976-18981.	0.0	0
1006	Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex. Journal of General Internal Medicine, 0, , .	2.6	0
1007	Canagliflozin ameliorates neuronal injury after cerebral ischemia reperfusion by targeting SGLT1 and AMPK-dependent apoptosis. Neurotherapeutics, 2024, 21, e00305.	4.4	0
1008	Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 0, 14, .	3.5	0
1009	Cardioâ€renalâ€metabolic disease in primary care setting. Diabetes/Metabolism Research and Reviews, 0, , .	4.0	1
1010	Worsening heart failure: a concept in evolution. Current Opinion in Cardiology, 2024, 39, 119-127.	1.8	0
1011	Safety of sodiumâ€glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and metaâ€analysis. ESC Heart Failure, 0, , .	3.1	0
1012	Effective medications can work only in patients who take them: Implications for postâ€acute heart failure care. European Journal of Heart Failure, 2024, 26, 1-4.	7.1	0

#	Article	IF	Citations
1013	KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases, 2024, 83, 277-287.	1.9	1
1014	Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis. World Journal of Nephrology, 0, 12, 182-200.	2.0	0
1015	Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218.	0.0	0
1016	<scp>Metaâ€analysis</scp> of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, Obesity and Metabolism, 2024, 26, 971-979.	4.4	0
1017	Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode. ESC Heart Failure, 0, , .	3.1	1
1018	Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure. American Journal of Medicine, 2024, 137, S25-S34.	1.5	0
1019	Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovascular Diabetology, 2024, 23, .	6.8	1
1020	Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis. Arthritis Research and Therapy, 2024, 26, .	3.5	0
1021	SGLT2 inhibitors in heart failure with preserved ejection fraction. Current Problems in Cardiology, 2024, 49, 102388.	2.4	0
1022	Sodium-Glucose Cotransporter 2 Inhibitors in South Australia: The Magic Before the Fame. Heart Lung and Circulation, 2023, 32, 1369-1377.	0.4	0
1023	Management of Heart Failure in Hospitalized Patients. Annals of Internal Medicine, 2023, 176, ITC177-ITC192.	3.9	0
1024	2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2024, 26, 5-17.	7.1	4
1028	Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 0, , .	3.0	0
1029	Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure. Scientific Reports, 2024, 14, .	3.3	0
1030	Medicines optimization prior to discharge in patients admitted to hospital with heart failure. ESC Heart Failure, 2024, 11, 950-961.	3.1	0
1031	Use of Non-insulin Agents for Hyperglycemia Management in Hospitalized Patients. Contemporary Endocrinology, 2023, , 77-91.	0.1	0
1032	Glycemic Management in Coronary Artery Bypass Graft Patients. Contemporary Endocrinology, 2023, , 307-322.	0.1	0
1034	Angiotensin Receptor Neprilysin Inhibition Across Ejection Fraction andÂAcuity Spectra in HeartÂFailure. JACC: Heart Failure, 2024, 12, 583-587.	4.1	0

#	Article	IF	Citations
1036	The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs. European Journal of Clinical Pharmacology, 2024, 80, 563-573.	1.9	0
1037	The effect of the four pharmacological pillars of heart failure on haemoglobin level. Annals of Medicine and Surgery, 2024, 86, 1575-1583.	1.1	0
1038	Uptake of Sodium-Glucose Cotransporter-2 Inhibitors in Hospitalized Patients With Heart Failure: Insights From the Veterans Affairs Healthcare System. Journal of Cardiac Failure, 2024, , .	1.7	0
1039	Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2024, 19, 557-564.	4.5	0
1040	Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis. Diabetes and Metabolism Journal, 2024, 48, 312-320.	4.7	0
1041	The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?. Journal of Personalized Medicine, 2024, 14, 141.	2.5	0
1042	Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights. International Journal of Molecular Sciences, 2024, 25, 1574.	4.1	0
1043	The Effect of SGLT-2i and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis. Journal of Cardiology and Cardiovascular Medicine, 2024, 9, 014-025.	0.2	0
1044	Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age and Ageing, 2024, 53, .	1.6	0
1046	Comparison of Effectiveness Among Different Sodiumâ€Glucose Cotransoporterâ€2 Inhibitors According to Underlying Conditions: A Network Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2024, 13, .	3.7	0
1048	Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature. Heart Failure Reviews, 2024, 29, 549-558.	3.9	0
1049	Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease. Journal of Cardiovascular Medicine, 2024, 25, 247-258.	1.5	0
1050	The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fractionâ€”A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Heart Lung and Circulation, 2024, 33, 197-208.	0.4	0
1051	Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systemsâ€”A Literature Review. International Journal of Molecular Sciences, 2024, 25, 1972.	4.1	0
1052	Emerging role of antidiabetic drugs in cardiorenal protection. Frontiers in Pharmacology, 0, 15, .	3.5	0
1054	The double burden: type 1 diabetes and heart failureâ€”a comprehensive review. Cardiovascular Diabetology, 2024, 23, .	6.8	0
1055	Latest pharmaceutical approaches across the spectrum of heart failure. Heart Failure Reviews, 2024, 29, 675-687.	3.9	0
1056	Determinants of Guideline-Directed Medical Therapy Implementation During HeartÂFailure Hospitalization. , 2024, , 100818.		0

#	Article	IF	Citations
1057	Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: AÂMetaâ€Regression Analysis. Journal of the American Heart Association, 2024, 13, .	3.7	1
1058	The effect of sodium glucose Co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients. Clinical Epidemiology and Global Health, 2024, 26, 101555.	1.9	0
1059	Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodiumâ€“Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure. International Journal of Molecular Sciences, 2024, 25, 2484.	4.1	0
1060	New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023. European Heart Journal - Cardiovascular Pharmacotherapy, 0, , .	3.0	0
1061	Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction â€“ a secondary analysis of TOPCAT. American Heart Journal, 2024, 271, 136-147.	2.7	0
1062	Enhancing patient outcomes: 2023 focused clinical update on heart failure. British Journal of Cardiac Nursing, 2024, 19, 1-9.	0.1	0
1063	Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon. Journal of Clinical Medicine, 2024, 13, 1375.	2.4	0
1064	Pros of Inpatient Sodium Glucose Cotransporter-2 Inhibitor Use. Endocrine Practice, 2024, 30, 398-401.	2.1	0
1065	Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a metaâ€analysis. ESC Heart Failure, 0, , .	3.1	0
1066	Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations. Heart International, 2023, 17, 12.	1.4	0
1067	Enhancing implementation of evidence-based heart failure therapies in clinical practice: vital to modern medicine. Cardiology Plus, 2024, 9, 6-8.	0.7	0
1068	Blood pressure and intensive treatment upâ€titration after acute heart failure hospitalization: Insights from the <scp>STRONGâ€HF</scp> trial. European Journal of Heart Failure, 0, , .	7.1	0
1069	Fasting Plasma Ketone Bodies Are Associated with NT-proBNP: A Potential Mechanism to Provide Fuel for the Failing Heart. Journal of Clinical Medicine, 2024, 13, 1541.	2.4	0
1070	Exploring the Efficacy of Sotagliflozin on Heart and Kidney Health in Diabetic Patients: A Comprehensive Meta-Analysis. Indian Journal of Community Medicine, 2024, 49, 269-278.	0.4	0
1071	2024 ACC Expert Consensus Decision Pathway for Treatment of HeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2024, 83, 1444-1488.	2.8	0
1072	Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement. ESC Heart Failure, 0, , .	3.1	0
1073	Enhanced Decongestive Therapy in Patients With Acute HeartÂFailure. Journal of the American College of Cardiology, 2024, 83, 1243-1252.	2.8	0
1074	Exploring the therapeutic potential of tetrahydrobiopterin for heart failure with preserved ejection fraction: A path forward. Life Sciences, 2024, 345, 122594.	4.3	0

#	Article	IF	Citations
1075	Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance. Cardiovascular Diabetology, 2024, 23, .	6.8	0
1076	Clinical Implications of Ventricular-Arterial Coupling and the Role of Therapeutic Interventions. , 2024, , 401-416.		0
1077	Acute Heart Failure. Cardiology Clinics, 2024, 42, 165-186.	2.2	0
1078	Sacubitril/Valsartan in Patients Hospitalized With Decompensated HeartÂFailure. Journal of the American College of Cardiology, 2024, 83, 1123-1132.	2.8	0
1079	CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovascular Diabetology, 2024, 23, .	6.8	0
1080	SGLT2 inhibitors: Beyond glycemic control. Journal of Clinical and Translational Endocrinology, 2024, 35, 100335.	1.4	0